Tiziana Life Sciences (TLSA) 20-F 17 Jun 20 2019 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2019shares
Document And Entity Information
Entity Registrant Name	Tiziana Life Sciences plc
Entity Central Index Key	0001723069
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	20-F
Document Period End Date	Dec. 31, 2019
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2019
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	Yes
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	136,654,516
Entity Incorporation State Country Code	X0
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 200	$ 5,304
Prepayments and other receivables	165	567
Finance lease receivable	143
Taxation receivable	675	1,018
Related party receivables	322	24
Total current assets	1,505	6,913
Property and Equipment, net	6	7
Finance lease receivable	149
Right of use asset	433
Other non-current assets	285
Total non-current assets	873	7
Total assets	2,378	6,920
Current liabilities:
Accounts payable and accrued expenses	6,396	5,954
Lease Liability	279
Related party payable	594	447
Other liabilities	82
Total current liabilities	7,351	6,401
Lease Liability (Non-Current)	541
Total liabilities	7,892	6,401
Shareholders' Equity:
Called up share capital (136,654,516 shares are issued and outstanding; 2018: 136,463,818)	8,599	8,592
Share premium	39,931	39,832
Share based payment reserve - Options	5,163	3,854
Share based payment reserve - warrants	2,419	1,874
Convertible loan note reserve	1,357
Other reserve	(46,171)	(46,171)
Translation reserve	1,940	1,967
Capital reduction reserve	41,292	41,292
Retained earnings	(60,044)	(50,721)
Total shareholders' equity	(5,514)	519
Total liabilities and shareholders' equity	$ 2,378	$ 6,920

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - shares	Dec. 31, 2019	Dec. 31, 2018
Statement of financial position [abstract]
Share capital, issued	136,654,516	136,463,818
Share capital, outstanding	136,654,516	136,463,818

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Profit or loss [abstract]
Cost of revenue
Gross Profit
Operating expenses:
Research and Development	(3,714)	(5,510)	(6,015)
Operating Expenses	(6,207)	(4,357)	(4,478)
Total operating expenses	(9,921)	(9,867)	(10,493)
Loss from operations	(9,921)	(9,867)	(10,493)
Other income/(expense):
Finance Income/(expense)	(91)	(12)	(12)
Loss from operations before income taxes	(10,012)	(9,879)	(10,505)
Income tax provision	689	1,945	1,912
Loss for the year	(9,323)	(7,934)	(8,593)
Other Comprehensive loss:
Currency translation	(27)	(21)	61
Comprehensive loss	$ (9,350)	$ (7,955)	$ (8,532)
Basic and diluted loss per share attributable to common shareholders	$ (0.07)	$ (0.06)	$ (0.09)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Share Capital	Share Premium	Share Based Payment Reserve (Options)	Share Based Payment Reserve (warrants)	Convertible Loan Note Reserve	Merger Reserve	Other Reserve	Retained Earnings	Capital Redemption Reserve	Translation Reserve	Capital Reduction Reserve	Total
Balance at Dec. 31, 2016	$ 6,903	$ 8,943	$ 2,647	$ 271	$ 17,158		$ (46,171)	$ (29,726)		$ 2,771	$ 41,292	$ 4,088
Balance, shares at Dec. 31, 2016	94,393,401
Statement Line Items [Line Items]
Prior period adjustment				648	(374)			(274)
Opening Balance as at 1 January 2018 (Restated)	6,903	8,943	2,647	919	17,158		(46,171)	(30,000)		2,771	41,292	4,088
Issue of share capital	$ 84	1,464										1,548
Issue of share capital, shares	2,206,190
Convertible loan note interest					3,610			(3,610)
Share based payment (warrants)		(726)		237	375							(114)
Convertible Loan Note Conversion	$ 1,154	20,877			(21,188)					(844)
Convertible Loan Note Conversion, shares	28,455,214
Share based payment (options)			1,324									1,324
Share based payment (warrants)				308								308
Convertible loan note - equity component					419			(419)
Option forfeited in the year			(758)									(758)
Options cancelled in the year								(142)				(142)
Total transactions with owners	$ 1,238	21,616	566	545	(16,784)			(4,171)		(844)		2,166
Total transactions with owners, shares	30,661,404
Comprehensive income
Loss for the period								(8,593)				(8,593)
Translation										61		61
Total comprehensive income								(8,593)		61		(8,532)
Balance at Dec. 31, 2017	$ 8,141	30,559	3,213	1,464			(46,171)	(42,764)		1,988	41,292	(2,278)
Balance, shares at Dec. 31, 2017	125,054,805
Statement Line Items [Line Items]
Issue of share capital	$ 451	9,556										10,007
Issue of share capital, shares	11,409,013
Convertible loan note interest	$ 1	22						(23)
Share based payment (options)			641									641
Share based payment (warrants)		(305)		410								105
Total transactions with owners	$ 452	9,273	641	410				(23)				10,752
Total transactions with owners, shares	190,698
Comprehensive income
Loss for the period								(7,934)				(7,934)
Translation										(21)		(21)
Total comprehensive income								(7,934)		(21)		(7,955)
Balance at Dec. 31, 2018	$ 8,592	39,832	3,854	1,874			(46,171)	(50,721)		1,967	41,292	519
Balance, shares at Dec. 31, 2018	136,463,818
Statement Line Items [Line Items]
Issue of share capital	$ 7	99										106
Issue of share capital, shares	190,698
Convertible loan note issued					1,850							1,850
Convertible loan note interest					52							52
Share based payment (options)			1,309									1,309
Share based payment (warrants)				545	(545)
Total transactions with owners	$ 7	99	1,309	545	1,357							3,317
Total transactions with owners, shares	190,698
Comprehensive income
Loss for the period								(9,323)				(9,323)
Translation										(27)		(27)
Total comprehensive income								(9,323)		(27)		(9,350)
Balance at Dec. 31, 2019	$ 8,599	$ 39,931	$ 5,163	$ 2,419	$ 1,357		$ (46,171)	$ (60,044)		$ 1,940	$ 41,292	$ (5,514)
Balance, shares at Dec. 31, 2019	136,654,516

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Loss from operations before income taxes	$ (10,012)	$ (9,879)	$ (10,505)
Adjustments to reconcile net loss to net cash used in operating activities:
Convertible loan interest accrued	50	12	12
Convertible loan interest paid as equity		21
Shares issued in lieu of fees	105	55
Share based payment - options	1,266	672	539
Cancellation of options			(135)
Share based payment - warrants		60	171
Net (increase) in related party receivables	(287)
Net increase in related party payables	436	144
Net (increase)/decrease in operating assets/other receivables	159	(180)	54
Net increase/(decrease) in operating liabilities /other liabilities	(23)	1,979	2,304
Depreciation	5	16	13
Loss on foreign exchange	165	(296)	45
Lease adjustment		3	(31)
Depreciation of right-of-use asset	248
Loss om disposal of right of use asset	71
Increase in taxation receivable	1,021	2,791
Net cash used in operating activities	(6,796)	(4,602)	(7,533)
CASH FLOWS FROM INVESTING ACTIVITIES
PPE	(4)		(1)
Acquisition of other investments
Net cash used in investing activities	(4)		(1)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of ordinary shares		9,917	1,542
Proceeds from issuance of convertible loan notes	1,880
Proceeds from issuance of warrants		1,509
Repayment of leasing liabilities	(200)
Fundraising cost		(1,335)
Net cash provided by financing activities	1,680	10,091	1,542
Net increase/(decrease) in cash and cash equivalents	(5,120)	5,489	(5,992)
Cash and cash equivalent, beginning of period	5,304	64	5,802
Exchange difference	16	(249)	254
Cash and cash equivalent, end of period	$ 200	$ 5,304	$ 64

General Information

General Information	12 Months Ended
	Dec. 31, 2019
General Information [Abstract]
GENERAL INFORMATION	1. GENERAL INFORMATION Tiziana Life Sciences PLC is a public limited company incorporated in the United Kingdom under the Companies Act and quoted on the AIM market of the London Stock Exchange (AIM: TILS) and on the NASDAQ Capital Market (NDAQ: TLSA). The address of its registered office is given on page 1. The principal activities of the Company and its subsidiaries (the Group) are that of a clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology. These financial statements are presented in thousands of dollars ($'000) which is the presentational currency of the company. The functional currency is pounds sterling (£) indicative of the primary economic environment in which the Company operates. The ultimate parent of the group is Planwise Group Limited, incorporated in the British Virgin Islands. Gabriele Cerrone is the ultimate beneficial owner of the entire issued share capital of Planwise Group Limited.

Accounting Policies

Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
ACCOUNTING POLICIES	2. ACCOUNTING POLICIES The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been applied consistently to all the years presented unless otherwise stated. Basis of preparation The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), and IFRIC interpretations as applicable to companies reporting under IFRS. These accounts have been prepared under the historical cost convention. Going Concern The Group incurred losses during the year and has net assets at the year end. The Group is in the early stages of developing its business focusing on the discovery and development of novel molecules that treat human disease in oncology and immunology. As the Group is pre-revenue, the Directors expect the Group to incur further losses and to require significant capital expenditure in continuing to develop clinical stage development therapeutic candidates in both oncology and immunology. The Group has successfully funded clinical trials to date and going forward will need to continue to secure additional investment to fund the clinical trials. The Directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment to fund that operation. On the basis of those projections, the directors conclude that the company will be able to meet its liabilities as they fall due for the next 12 months from the date when these financial statements are issued. Until and unless the Group and Company secures sufficient investment to fund their clinical pipeline, there is a material uncertainty about the Group and Company's ability to continue as a going concern after the next 12 months, and therefore about the applicability of the going concern basis of preparation. The financial statements do not include the adjustments that would be required if the going concern basis of preparation was considered inappropriate. The directors do not believe that Brexit will have an impact on the Group's ability to raise funds as it has access to the US market due to its listing on the Nasdaq. Basis of consolidation Subsidiary undertakings are all entities over which the Group exercises control. The Group has control when it can demonstrate all of the following: (a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability to use its power over the investee to affect the amount of the investor's return. The existence and effect of both current voting rights and potential voting rights that are currently exercisable or convertible are considered when assessing whether control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control and are de-consolidated from the date at which control ceases. Business combination The consolidated position of the Group is as a result of the reverse acquisition of Alexander David Investments plc by Tiziana Pharma Ltd and the subsequent listing of the Company as Tiziana Life Sciences Plc on 24 April 2014. Tiziana Pharma Limited was incorporated on 4 November 2013 and prepared its first set of financial statements to 31 December 2014. Therefore, the parent and subsidiary had the same reporting date but Tiziana Pharma Limited had a long period of account. No adjustment was made in the consolidated financial statements for the difference in length of reporting period because the only transaction in Tiziana Pharma Limited at 31 December 2013 was the issue of ordinary share capital of £1. Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the Board. The Board allocates resources to and assess the performance of the segments. The Board considers there to be only one operating segment being the research and development of biotechnological and pharmaceutical products. Taxation The tax expense for the year represents the total of current taxation and deferred taxation. The charge in respect of current taxation is based on the estimated taxable profit for the year. Taxable profit for the year is based on the profit as shown in the income statement, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes. The current tax liability for the year is calculated using tax rates which have either been enacted or substantively enacted at the balance sheet date. Deferred tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and expected to apply when the related deferred tax is realized, or the deferred liability is settled. Deferred tax assets are recognized to the extent that it is probable that the future taxable profit will be available against which the temporary differences can be utilized. Research and Development tax credits are provided for in the year that the costs are incurred. These are estimated based on eligible research and development expenditure. Any difference rebated are recognized in the following year, when the cash is received from the UK tax authorities. Foreign currency translation Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates (the functional currency). The consolidated financial statements are presented in US dollars, which is the Group's presentation currency. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement. The financial statements of overseas subsidiary undertakings are translated into US dollars on the following basis: ● Assets and liabilities at the rate of exchange ruling at the year-end date. ● Profit and loss account items at the average rate of exchange for the year. Exchange differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation. License fees Payments related to the acquisition of rights to a product or technology are capitalised as intangible assets if it is probable that future economic benefits from the asset will flow to the entity and the cost of the asset can be reliably measured. Payments made which provide the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire an asset. Licence fees expenses are recognised as incurred. Research and development All on-going research and development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment inherent in the development of the Group's products, the criteria for development costs to be recognised as an asset, as set out in IAS 38 'Intangible Assets', are not met until a product has been granted regulatory approval and it is probable that future economic benefit will flow to the Group. The Group currently has no qualifying expenditure. Financial instruments The Group classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument. The Group evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component. Such components shall be classified separately as financial assets, financial liabilities or equity instruments. A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. (a) Financial assets, initial recognition and measurement and subsequent measurement All financial assets not recorded at fair value through profit or loss, such as receivables and deposits, are recognized initially at fair value plus transaction costs. Financial assets carried at fair value through profit or loss are initially recognized at fair value, and transaction costs are expensed in the income statement. The measurement of financial assets depends on their classification. Financial assets such as receivables and deposits are subsequently measured at amortized cost using the effective interest method, less loss allowance. The Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive income. (b) Financial liabilities, initial recognition and measurement and subsequent measurement Financial liabilities are classified as measured at amortized cost or FVTPL. A financial liability is classified as at FVTPL if it is a derivative. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss. The Group's financial liabilities include trade and other payables. Warrants Warrants issued by the Group to investors as part of a share subscription are compound financial instruments where the warrant meets the definition of a financial liability. The financial liability component is initially measured at fair value in the Consolidated Statement of Financial Position. Equity is measured at the residual between the subscription price for the entire instrument and the liability component. The financial liability component is remeasured depending on its classification. Equity is not remeasured. Investments Investments are held as non-current assets and comprise investments in subsidiary undertakings and are stated at cost less provision for any impairment. Share capital Ordinary shares of the Company are classified as equity. Property, plant and equipment (i Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalised as part of that equipment. When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognised in profit or loss. (ii) Depreciation Depreciation is calculated on the depreciable amount, which is the cost of an asset, or other amount substituted for cost, less its residual value. Depreciation is recognised in profit or loss on a straight-line basis over the estimated useful life of each part of an item of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. The estimated useful lives for the current period and the comparative period are as follows. Fixtures and fittings 5 years IT and equipment 3 years Depreciation methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line of the income statement. Impairment Impairment of financial assets measured at amortised cost At each reporting date the Group recognises a loss allowance for expected credit losses on financial assets measured at amortised cost. In establishing the appropriate amount of loss allowance to be recognised, the Group applies either the general approach or the simplified approach, depending on the nature of the underlying group of financial assets. General approach The general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted cash and cash and cash equivalents. Under the general approach the Group recognises a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses, unless the credit risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is recognised at an amount equal to the lifetime expected credit losses. Simplified approach The simplified approach is applied to the impairment assessment of trade receivables. Under the simplified approach the Group always recognises a loss allowance for a financial asset at an amount equal to the lifetime expected credit losses. Non-financial assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Non-financial assets are impaired when its carrying amount exceed its recoverable amount. The recoverable amount is measured as the higher of fair value less cost of disposal and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present value. Leases IFRS 16 Leases was issued in January 2016 and was implemented by the Group from 1 January 2019. The Standard replaces IAS 17 and requires lease liabilities and 'right of use' assets to be recognised on the balance sheet for almost all leases. The adoption methodology of IFRS 16 is the cumulative catch-up method, and the impact of adoption was to recognise a right of use asset of $1,098k and a lease liability of $1,098k on 1 January, 2019. Fair Value Measurement Management have assessed the categorisation of the fair value measurements using the IFRS 13 fair value hierarchy. Categorisation within the hierarchy has been determined on the basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows; Level 1 - valued using quoted prices in active markets for identical assets Level 2 - valued by reference to valuation techniques using observable inputs other than quoted prices included within Level 1; Level 3 - valued by reference to valuation techniques using inputs that are not based on observable market data. Share based payments The calculation of the fair value of equity-settled share based awards and the resulting charge to the statement of comprehensive income requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the Company's share price. These assumptions are then applied to a recognised valuation model in order to calculate the fair value of the awards. Where employees, directors or advisers are rewarded using share based payments, the fair value of the employees', directors' or advisers' services are determined by reference to the fair value of the share options/warrants awarded. Their value is appraised at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets). Warrants issued in association with the issue of Convertible Loan Notes are also considered as share based payments and a share based payment charge is calculated for these too. In accordance with IFRS 2, a charge is made to the statement of comprehensive income for all share-based payments including share options based upon the fair value of the instrument used. A corresponding credit is made to a share based payment reserve - options, in the case of options/warrants awarded to employees, directors, advisers and other consultants. If vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share options/warrants expected to vest. Non market vesting conditions are included in assumptions about the number of options / warrants that are expected to become exercisable. Estimates are subsequently revised, if there is any indication that the number of share options/warrants expected to vest differs from previous estimates. No adjustment is made to the expense or share issue cost recognised in prior periods if fewer share options ultimately are exercised than originally estimated. Upon exercise of share options/warrants, the proceeds received are allocated to share capital with any excess being recorded as share premium. Where share options are cancelled, this is treated as an acceleration of the vesting period of the options. The amount that otherwise would have been recognised for services received over the remainder of the vesting period is recognised immediately within the Statement of Comprehensive Income. All goods and services received in exchange for the grant of any share based payment are measured at their fair value. Convertible loan notes Where there is no option to repay in cash or the Company has the choice of settlement, and the interest rate is fixed The Group considers these to be convertible equity instruments and records the principal of the loan note as an equity in a Convertible loan note reserve. The accrued interest on the principal amount, for which there is no obligation to settle in cash, is also recorded in the Convertible loan note reserve. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from the convertible loan note reserve to share capital and share premium. Where the above conditions are not met The Group considers these to be convertible debt instruments and records the principal of the loan note as a debt liability in the liabilities section of the statement of financial position. The accrued interest on the principal amount is recorded in the income statement and as an increase in the debt liability. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from the debt liability to share capital and share premium. Under IAS 32 the liability and equity components of convertible loan notes must be presented separately on the statement of financial position. The Group has examined the terms of each issue of convertible loan notes and determined their accounting treatment accordingly. Convertible loan notes are treated differently depending upon a number of factors.

Critical Accounting Estimates a

Critical Accounting Estimates and Judgements	12 Months Ended
	Dec. 31, 2019
Critical Accounting Estimates and Judgements [Abstract]
CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS	3. CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS The preparation of financial information in accordance with generally accepted accounting practice, in the case of the Group being International Financial Reporting Standards as adopted by the European Union, requires the directors to make estimates and judgements that affect the reported amount of assets, liabilities, income and expenditure and the disclosures made in the financial statements. Such estimates and judgements must be continually evaluated based on historical experience and other factors, including expectations of future events. When entering into agreements with third parties which provide the rights to conduct research into specific biological processes the group account for these agreements as an expense if the agreements are ‘milestone’ in nature and relate to the Group’s own research and development costs. Such agreements involve periodic payments and are evaluated as representing payments made to fund research. The only other critical accounting estimates and judgements in the preparation of the financial statements were fair value estimates used in the calculation of share based payments and warrants which have been detailed above in note 2, accounting policies, and note 16, share based payments, to the accounts. The Group has also made a judgement on the impact of Brexit during the preparation of the financial statements and considered it to not be significant.

Changes in Accouting Policies a

Changes in Accouting Policies and Prior Year Adjustments	12 Months Ended
	Dec. 31, 2019
Changes in Accouting Policies and Prior Year Adjustments [Abstract]
CHANGES IN ACCOUTING POLICIES AND PRIOR YEAR ADJUSTMENTS	4 CHANGES IN ACCOUTING POLICIES AND PRIOR YEAR ADJUSTMENTS IFRS 16 Leases The group has adopted IFRS 16 retrospectively from 1 January 2019 but has not restated comparatives for the 2018 reporting period, as permitted under the specific transitional provisions in the standard. The reclassifications and the adjustments arising from the new leasing rules are therefore recognised in the opening balance sheet on 1 January 2019. On adoption of IFRS 16, the group recognised lease liabilities in relation to leases which had previously been classified as 'operating leases' under the principles of IAS 17 Leases. These liabilities were measured at the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate as of 1 January 2019. The weighted average lessee's incremental borrowing rate applied to the lease liabilities on 1 January 2019 was 3.35%. The Group assesses whether a contract is or contains a lease at inception of the contract. The Group recognises a right-of-use assets and corresponding lease liabilities at the lease commencement date, except for short term leases and leases of low value. For these leases, the lease payments are recognised as an operating expense on a straight-line basis over the term of term of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liabilities adjusted for any lease payments made at or before the commencement date, plus any initial costs incurred. The right-of-use assets are subsequently measured at cost less accumulated depreciation and impairment losses. The right-of-use assets are from the commencement date depreciated over the shorter period of lease term and useful life of the underlying asset. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-of-use assets are periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liabilities, e.g. revised discount rate, change in the lease term or change in future lease payments resulting from a change in an index. The lease liabilities are initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate determined by the Group's borrowing rate. 2019 $000 Operating lease commitments disclosed under IAS17 as at 31 December 2018 1,142 Remaining lease commitments discounted using the Group's incremental borrowing rate as at the date of initial application 1,098 Lease Liability recognised as at 1 January 2019 1,098 Of which: Current lease liabilities 260 Non-current lease liabilities 839 The associated right-of-use assets for all leases were measured at the amount equal to the lease liability. The recognised right-of-use assets relate to the following types of assets: 31 December 1 January $000 $000 Properties 433 1,098 Total right-of-use assets 433 1,098 In applying IFRS 16 for the first time, the group has used the following practical expedients permitted by the standard: ● the use of a single discount rate of 3.35% to a portfolio of leases with reasonably similar characteristics; ● the use of hindsight in determining the lease term where the contract contains options to extend or terminate the lease. Accounting for Warrants – Prior period adjustment During the year, the Group reviewed its accounting treatment for warrants. The Group has warrants that had been issued in lieu of fees and warrants that had been issued as an additional incentive for investors to enter into a Convertible Loan Note agreement. Warrants issued in lieu of fees In prior years the fair value at date of grant had been expensed to the Statement of Income based on the vesting period of the warrant. The Group recognises that the fair value at the date of grant should be recognised over the life of the service for which the warrant was provided. Warrants issued as incentive In prior years the fair value at date of grant had been expensed to the Statement of Income based on the vesting period of the warrant. The Group recognises that the fair value of the warrants should be recognised as a cost of fundraising and fully recognised at the date of issuance of the Convertible Loan Note. The adjustments have impacted the prior period and earlier periods and the impact on the financial statements is as follows: 1 January Adjustment 1 January $'000 $'000 $'000 Consolidated Balance Sheet (Extract) Convertible loan note reserve 17,158 (374 ) (16,784 ) Share based payment reserve (warrants) 271 648 919 Retained Earnings (29,726 ) (274 ) (30,000 ) Total Equity 4,0883 - 4,088 ) 31 December Adjustment 31 December $'000 $'000 $'000 Consolidated Balance Sheet (Extract) Share Premium 31,284 (725 ) 30,559 Share based payment reserve (warrants) 579 885 1,464 Translation reserve 1997 (9 ) 1,988 Retained Earnings (42,613 ) (151 ) (42,764 ) Total Equity (2,278 ) - (2,278 ) 31 December Adjustment 31 December $'000 $'000 $'000 Consolidated Balance Sheet (Extract) Share Premium 40,862 (1,030 ) 39,832 Share based payment reserve (warrants) 743 1,131 1,874 Translation reserve 1977 (91 ) 1,967 Retained Earnings 50,630 ) (10 ) (50,721 ) Total Equity 519 - 519 31 December Adjustment 31 December $'000 $'000 $'000 Consolidated Statement of Comprehensive Income (Extract) Operating Expenses (4,418 ) 60 (4,358 ) Loss before taxation (9,939 ) 60 (9,879 )

Operating Loss

Operating Loss	12 Months Ended
	Dec. 31, 2019
Operating Loss [Abstract]
OPERATING LOSS	5. OPERATING LOSS The Group and Company's operating loss are stated after charging the following: Year Ended 2019 2018 2016 License fee 553 662 662 Depreciation of Property, Plant and Equipment 5 13 13 Depreciation (Right-of-use asset) 245 Foreign exchange (gain)/losses 165 45 45 967 720 720

Segmental Reporting

Segmental Reporting	12 Months Ended
	Dec. 31, 2019
Segmental Reporting [Abstract]
SEGMENTAL REPORTING	6. SEGMENTAL REPORTING During the year under review Management identified the Group's only operating segment as the research and development of biotechnological and pharmaceutical products. This one segment is monitored and strategic decisions are made based upon it and other non-financial data collated from industry intelligence. The form of financial reporting reported to the Board is consistent with those presented in the annual financial statements.

Employees

Employees	12 Months Ended
	Dec. 31, 2019
Employees [Abstract]
EMPLOYEES	7. EMPLOYEES Year ended 2019 $'000 2018 2017 Group Staff costs comprised: Directors' salaries (including bonus) 1,145 606 457 Employee's wages, salaries and bonus 696 712 861 Social security costs 609 491 491 Share based payment charge 1,266 539 539 3,716 2,348 2,348 The average monthly number of employees, including directors, employed by the group during the year was: Research and Development 5 6 6 Corporate and administration 4 5 5 9 11 11

Remuneration of Key Management

Remuneration of Key Management Personnel	12 Months Ended
	Dec. 31, 2019
Remuneration of Key Management Personnel [Abstract]
REMUNERATION OF KEY MANAGEMENT PERSONNEL	8. REMUNERATION OF KEY MANAGEMENT PERSONNEL Year ended $'000 2019 2018 2017 Directors Bonus Salary Directors Bonus Salary Directors Salary W Simon 48 - - 51 - - 49 - G. Cerrone (1) 102 182 - 124 - - 86 - R. Dalla-Favera 3 - - 26 - - 26 - K. Shailubhai (2) - 210 600 - 105 300 10 286 153 392 600 201 105 300 171 286 (1) Gabriele Cerrone's bonus covers the period June 9, 2016 to December 31, 2019 (2) Kunwar Shailubhai became an employee of the company on May 24, 2017, at which point he ceased to be a non-executive director. The following share options were granted to directors in the following periods: Year ended 2019 2018 2017 Number of options Number of options Number of options G. Cerrone - 550,000 - K. Shailubhai - 6,500,000 400,000 L. Zanbeletti - 550,000 - 7,600,000 400,000 The key management personnel of the Group are considered to be represented by the directors and officers of the company. No director has yet benefitted from any increase in the value of share capital since issuance of the options. No director exercised share options in the year. For the year ended December 31, 2019, the company made $15k (2018: $17k; 2017: $6k) of payments to defined contribution pension schemes on behalf of directors or employees.

Finance Costs

Finance Costs	12 Months Ended
	Dec. 31, 2019
Finance Costs [Abstract]
FINANCE COSTS	9 . FINANCE COSTS Year ended 2019 2018 2017 Group Finance Income Finance income received on net investment in lease 1 - - Total finance income 1 - - Finance Expense Finance charge accrued on convertible loan notes 61 12 12 Interest expense on lease liabilities 31 - - Total finance Expense 92 12 12 Total Finance Cost 92 12 12

Taxation

Taxation	12 Months Ended
	Dec. 31, 2019
Taxation [Abstract]
TAXATION	10. TAXATION Year Ended 2019 2018 2017 Group Current year tax (credit) (661 ) (1,067 ) (489 Adjustments due to prior periods (28 ) (879 ) (1,423 ) Total tax (credit) for the period (689 ) (1,945 ) (1,912 ) The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 21.49%. The difference can be reconciled as follows: Loss before taxation (10,013 ) (9,939 ) (10,628 ) Loss charged at standard rate of corporation tax 19 % (2018: 19%; 2017: 19.25%) (1,903 ) (1,888 ) (2,046 ) Other timing differences - 1,104 2,889 Movement in unrecognised deferred tax (241 ) - - Expenses not deductible for taxation 1,727 176 31 Adjustments due to prior periods (28 ) (879 ) (1,423 ) Research and development claim (285 ) (459 ) (1,366 Consolidation adjustment in relation to foreign exchange movements (689 ) - - Other timing differences - - 3 (689 ) (1,945 ) (1,912 ) The Research and Development claim has been calculated in accordance with the R&D tax relief available to small and medium sized entities, whereby the entity is able to claim a cash tax credit (if loss making), worth up to 14.5% of the surrenderable losses. The adjustments due to prior periods relates to R&D tax relief claims for the prior period. Under UK tax legislation, a 2 year window is available under which R&D tax relief can be claimed. No deferred tax asset has been recognized in respect of trading losses carried forward because of uncertainty as to when these losses will be recoverable. The amount of tax losses for which no deferred tax assets has been recognized for the year ended December 31, 2019 is $3,517 (2018; $3,928; 2017; $4,738).

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2019
Loss Per Share [Abstract]
LOSS PER SHARE	11. LOSS PER SHARE Basic loss per share is calculated by dividing the profit attributable to equity holders of the company by the weighted average number of ordinary shares in issue during the year. Year ended 2019 2018 (Restated) 2017 (Loss) attributable to equity holders of the company ($000) (9,323 ) (7,934 ) (8,716 ) Weighted average number of ordinary shares in issue 136,482,627 127,553,866 106,403,903 Basic loss per share (cents per share) (6.83 ) (6.22 ) (8.59 ) As the Group is reporting a loss from continuing operations for the year then, in accordance with IAS 33, the share options are not considered dilutive because the exercise of the share options would have an anti-dilutive effect. The basic and diluted earnings per share as presented on the face of the income statement are therefore identical. All earnings per share figures presented above arise from continuing and total operations and therefore no earnings per share for discontinued operations are presented. The earnings have been amended to include the interest accrued on Convertible Loan Notes.

Property, IT and Equipment

Property, IT and Equipment	12 Months Ended
	Dec. 31, 2019
Property IT and Equipment [Abstract]
PROPERTY, IT AND EQUIPMENT	12. PROPERTY, IT AND EQUIPMENT Details of the Groups property, IT and equipment are as follows: $000 Furniture IT Total Cost At 1 January 2018 15 31 46 Additions - - - Disposals - - - At 31 December 2018 15 31 46 Depreciation At 1 January 2018 3 20 23 Charge in year 6 10 16 At 31 December 2018 9 30 39 Net Book Value as at 31 December 2018 6 1 7 $000 Furniture IT Total Cost At 1 January 2019 15 31 46 Additions - 4 4 Disposals - - - At 31 December 2019 15 35 50 Depreciation At 1 January 2019 9 30 39 Charge in year 3 2 5 At 31 December 2019 12 32 44 Net Book Value as at 31 December 2019 3 3 6

Other Receivables

Other Receivables	12 Months Ended
	Dec. 31, 2019
Other Receivables [Abstract]
OTHER RECEIVABLES	13. OTHER RECEIVABLES $000 Year ended 2019 2018 Group Other receivables 134 246 Taxation receivable 676 1,019 Related party receivable 324 25 Prepayments 28 42 Other current assets - 276 1,162 1,609 There are no differences between the carrying amount and fair value of any of the trade and other receivables above.

Other Assets

Other Assets	12 Months Ended
	Dec. 31, 2019
Other Assets [Abstract]
OTHER ASSETS	14. OTHER ASSETS In June 2016, the Board approved the purchase of the data repository of DNA samples from SharDNA (an Italian entity in liquidation) for EUR 258k, approximately £217k and $268k. Management recognizes that the transaction is not the purchase of a business but the purchase of key assets owned by SharDNA. These assets are owned by Tiziana Life Sciences PLC. The validity to the sale of the assets has been confirmed by the Italian judicial system. The Company is still unable to utilise these assets until the resolution of the outstanding data protection legal action. For this reason, the investment has been recognised as a non-current asset until such a time that the Company is able to use this asset. The Company has not recognised a contingent liability in respect of the legal action as the outcome is uncertain and cannot be considered as probable to occur.

Finance Lease Receivable

Finance Lease Receivable	12 Months Ended
	Dec. 31, 2019
Convertible Equity Instrument [Abstract]
Finance Lease Receivable	15. FINANCE LEASE RECEIVABLE In November 2019, the Group subleased one of its leased office spaces in its entirety. The sublease runs for the remaining term of the original lease, until October 2021. The sublease has been classified as a finance lease receivable Finance lease receivable 31 Dec 2019 1 Jan 2019 $000 $000 Current 142 - Non-current 149 - 292 - The undiscounted lease payments to be received over the next 5 years are as follows: 1 Year 2 years 3 or more years $000 $000 £000 Undiscounted lease payments receivable 149 150 - 149 150 - During the year ending December 31 2019, the Group received $34k of income from its subleasing activities. Finance Lease Receivable 31 December 2019 $000 Finance Lease receivable as at 1 Nov 2018 327 Sublease income (36 ) 292

Investments in Subsidiaries

Investments in Subsidiaries	12 Months Ended
	Dec. 31, 2019
Disclosure of subsidiaries [abstract]
INVESTMENTS IN SUBSIDIARIES	16. INVESTMENTS IN SUBSIDIARIES The company's interest in subsidiary undertakings is as follows: Name Principal activity Registered Address Percentage shareholding Country of incorporation Tiziana Pharma Limited Clinical stage biotechnology company 3 rd 100 % England & Wales Tiziana Therapeutics, Inc. Clinical stage biotechnology company 420 Lexington Avenue 100 % USA Longevia Genomics SRL Biotech Discovery Company Via Constantinpoli 42 100 % Italy Tiziana Therapeutics, Inc. was incorporated on 28 October 2015. This entity was set up to house the company's US operations. Longevia Genomics SRL was incorporated on 4 July 2016. This entity was established to enable the company to carry out R&D activities in Sardinia.

Share Capital

Share Capital	12 Months Ended
	Dec. 31, 2019
Disclosure of classes of share capital [abstract]
SHARE CAPITAL	17. SHARE CAPITAL Company and Group 2019 2018 2019 2018 2019 2018 Ordinary Shares Deferred Shares $000 In issue at 1 January 136,463,818 125,054,805 - - 8,592 8,141 Issued for cash - 7,742,167 - - - 311 Issued in lieu of consultancy fees 190,698 - - - 7 - Conversion of Convertible Loan notes - - - - - - Conversion of warrants - 1,454,644 - - - 56 Conversion of Loan - 2,137,625 - 82 In lieu of commission - 74,577 - - - 2 In issue at 31 December 136,654,516 136,463,818 - - 8,599 8,592 Ordinary Shares Ordinary shares have a par value of £0.03. They entitle the holder to participate in dividends, and to share in the proceeds of winding up the company in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote. The company does not have a limited amount of authorized capital. Issuance of ordinary shares In November 2019, 190,968 new ordinary shares were issued in lieu of a consultancy fee of $105,000.

Share Based Payments

Share Based Payments	12 Months Ended
	Dec. 31, 2019
Share Based Payments [Abstract]
SHARE BASED PAYMENTS	18. SHARE BASED PAYMENTS Group and Company Options The company operates share-based payment arrangements to remunerate directors and key employees in the form of a share option scheme. The exercise price of the option is normally equal to the market price of an ordinary share in the company at the date of grant. 2019 2018 2017 Weighted Weighted Weighted Average exercise price (cents) Options Average exercise price (cents) Options Average exercise price (cents) Options Outstanding at 1 January 107 18,617 125 10,717 90 12,449 Granted - - 104 9,500 216 668 Forfeited (152 ) (2,238 ) (219 ) (1,600 ) (20 ) (2,400 ) Outstanding at 31 December 113 16,379 107 18,617 125 10,717 Exercisable at 31 December 67 5,521 50 5,236 57 5,011 No options were exercised during the years ended 31st December 2019, 2018 and 2017. The total outstanding fair value of the share option instruments is deemed to be approximately $5,011k as at December 31, 2019 (2018: $6,591k; 2017: $6,217k). The Directors have used the Black-Scholes option pricing model to estimate the fair value of most of the options applying the assumptions below. Historical volatility relies in part on the historical volatility of a group of peer companies that management believes is generally comparable to the company. The company has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future. The company has estimated a forfeiture rate of zero. 30 April 30 August 2017 10 March Grant date share price $ 1.041 $ 2.156 $ 2.331 Exercise share price $ 1.041 $ 2.156 $ 2.331 Vesting periods Yr1, Yr 2, Yr 3, Yr4 Yr 1, Yr 2, Yr 3, Yr4 Yr1, Yr 2, Yr 3, Yr4 Risk free rate 0.69% to 1.03 % 0.69% to 1.09 % 0.38% to 1.09 % Expected volatility 58% to 60 % 58% to 60 % 80% to 167 % Option life 10 years 10 years 10 years Weighted average share price $ 1.041 $ 2.156 $ 2.331 Weighted average fair value per share option $ 0.484 $ 0.770 $ 1.433 For the options issued with a market condition attached, the Directors have used the Monte Carlo simulation to estimate the fair value of these options, the company uses the following methods to determine its underlying assumptions: ● expected volatilities are based on the historical volatilities of the market ● the expected term of the awards is 15 years based on managements' assessment of when the market condition is likely to be achieved ● a range of fair values per share were produced and management have determined the most appropriate value based on their knowledge of the market and vesting conditions being fulfilled. Warrants On March 2, 2015, warrants were granted over 600,000 shares at an exercise price of $0.74 per share in lieu of the issue of options. The warrants are exercisable until December 31, 2021. On May 31, 2015, warrants were granted over 292,500 shares at an exercise price of $0.97 per share in lieu of fundraising fees. The warrants are exercisable until May 31, 2022. On November 11, 2017, warrants were granted over 100,000 shares at an exercise price of $2.16 per share in conjunction with a Convertible Loan Note. The warrants are exercisable until November 20, 2022. On December 11, 2017, warrants were granted over 183,333 shares at an exercise price of $2.16 per share in conjunction with a Convertible Loan Note. The warrants are exercisable until December 11, 2023. On December 15, 2017, warrants were granted over 196,667 shares at an exercise price of $2.16 per share in conjunction with a Convertible Loan Note. The warrants are exercisable until December 15, 2023. On January 16, 2018, warrants were granted over 63,334 shares at an exercise price of $2.046 per share in lieu of fundraising fees. The warrants are exercisable until January 15, 2024. On January 22, 2018, warrants were granted over 133,333 shares at an exercise price of $2.04 per share in conjunction with a Convertible Loan Note. The warrants are exercisable until January 22, 2024. On March 5, 2018, warrants were granted over 78,000 shares at an exercise price of $2.04 per share in lieu of fundraising fees. The warrants are exercisable until March 5, 2024. On April 19, 2018, warrants were granted over 51,563 shares at an exercise price of $1.02 per share in lieu of fundraising fees. The warrants are exercisable until April 19, 2024. On November 28, 2018, warrants were granted over 185,000 shares at an exercise price of $1.02 per share in lieu connection with the issuance and conversion of a loan. The warrants are exercisable until November 27, 2023. On November 28, 2018, warrants were granted over 150,000 shares at an exercise price of $1.02 per share in connection with the issuance and conversion of a loan. The warrants are exercisable until November 27, 2023. On October 31, 2019, warrants were granted over 185,950 shares at an exercise price of $0.55 per share in in lieu of fundraising fees. The warrants are exercisable until 31 October 2024. On October 31, 2019, warrants were granted over 1,289,372 shares at an exercise price of $0.55 per share in connection with the issuance of a convertible loan note. The warrants are exercisable until October 31, 2024. As disclosed in Note 3, the Group has made an adjustment to its accounting treatment of warrants this year. The Directors have estimated the fair value of the warrants in services provided using the Black-Scholes valuation model and assumptions above. For each set of warrants, the charge has been expensed over the service period. A share based payment charge for the year of $nil (year to December 2018, restated: $59k) has been expensed in the statement of comprehensive income.

Convertible Debt Instrument

Convertible Debt Instrument	12 Months Ended
	Dec. 31, 2019
Convertible Loan Notes [Abstract]
CONVERTIBLE LOAN NOTES	19. CONVERTIBLE DEBT INSTRUMENT Group and Company Planwise Convertible Debt Instrument 2016 From the date of the reverse acquisition a convertible loan note of $247k was in existence as detailed in the Admission Document dated 31 March 2014. Proceeds of the subscriptions for the notes are to be used exclusively to finance the company's on-going working capital requirements. The terms of the loan note are that the loan notes, plus accrued interest at a rate of 4 per cent above Bank of England base rate per annum, will convert into ordinary shares in the company at a price of £0.10 per share at the election of Planwise any time after the second anniversary of the readmission to AIM on 24 April 2014. The company considers this to be a Convertible Debt Instrument as detailed in the policy described at note 2. Accounting for the convertible debt instrument The net proceeds received from the issue of the Planwise Convertible Loan Note has been recorded as a debt liability in the balance sheet and the accrued interest charged to the income statement and the debt liability. The liability for the convertible debt instrument is; Planwise Convertible Loan Note Year ended 2019 2018 2017 $000 $000 $000 Convertible loan notes issued 302 290 278 Accrued interest 11 11 12 313 302 290

Convertible Instruments Classif

Convertible Instruments Classified as Equity	12 Months Ended
	Dec. 31, 2019
Convertible Equity Instrument [Abstract]
CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY	20. CONVERTIBLE INSTRUMENTS CLASSIFIED AS EQUITY On October 31, 2019, the Company decided to raise convertible equity finance from supportive existing shareholders. $1,850,000 was raised from the issuance of Convertible Loan Notes. The Loan Notes are short term instruments and carry a coupon of 16% per annum and are convertible (together with all accrued interest) into ordinary shares of nominal value £0.03 each in the capital of the Company at a conversion price of 42p, they are not convertible into cash. The Loan Notes are convertible on the third anniversary of the date of issue of the Notes, or at the election of the noteholder on completion of the next non-qualifying equity financing or on the making of a takeover offer for the Company(as defined in the City Code on Takeovers and Mergers), and such election may be made on an immediate basis or conditional on any such takeover offer being declared, or becoming, unconditional. The warrants issued in connection with the Loan Notes entitle the holders to subscribe for one additional share per conversion share at the same price of 42p. The warrants may be exercised for a period of up to 5 years from their date of issue. The principal amount of the Convertible Equity Instrument that was recorded as in the convertible loan note reserve prior to conversion is as follows: 2019 $000 Par value of cConvertible loan notes issued 1,850 Less: Fair value of warrants issued to note holders (545 ) 1,305 Accrued interest 52 1,357

Reserves

Reserves	12 Months Ended
	Dec. 31, 2019
Reserves [Abstract]
RESERVES	21. RESERVES The share based payment reserve for warrants represent the value of equity shares which could be issued in future accounting periods if the warrants in issue are exercised. The share based payment reserve for options represents the value of equity shares which could be issued in future accounting periods if the share based payment options in issue are exercised. The convertible loan note reserve represents the value of equity shares which could be issued in future accounting periods if the convertible loan notes are converted into equity. The other reserve was created as a result of the reverse acquisition of Alexander David Investments Plc, which is described in note 2. The reserve is required due to the fact that the reverse acquisition accounting requires the legal parent's equity structure to be shown. Retained earnings represent the cumulative profits/(losses) of the entity which have not been distributed to shareholders. This reserve has been credited as part of the capital reduction exercise described below. On the 14 of September 2016 the High Court granted the Company permission to cancel its share premium account and its capital redemption reserve. The order had previously been ratified at the AGM held on 30 June 2016. The £31.1m of distributable reserves arising from this transaction were taken to the capital reduction reserve. The Company also decided to cancel its merger relief reserve as part of the capital reduction exercise. The translation reserve represents the unrealised gains or losses from the foreign currency translation of Companies within the Group.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2019
Financial Instruments [Abstract]
FINANCIAL INSTRUMENTS	22. FINANCIAL INSTRUMENTS The main risks arising from the Group's financial instruments are liquidity risk, foreign currency risk and credit risk. The directors regularly review and agree policies for managing each of these risks which are summarized below. Market risk Market risk encompasses three types of risk, being foreign currency exchange risk, price risk and fair value interest rate risk. The Group policies for managing fair value interest rate risk are considered along with those for managing cash flow interest rate risk and are set out in the subsection entitled "interest rate risk" below. The directors do not consider the Group's exposure to price risk to be significant. The Group's risk management is coordinated by the directors, and focuses on actively securing the Group's short to medium term cash flows by minimizing the exposure to financial markets. The Group does not engage in the trading of financial assets for speculative purposes nor does it write options. Credit risk Credit risk is managed on a group basis. Credit risk arises principally from cash and cash equivalents and deposits with banks and financial institutions as well as credit exposure to customers including committed transactions and outstanding receivables. The group reviews its banking arrangements carefully to minimize such risks and currently has no customers and therefore this risk is viewed as minimal. Management monitor loans between members of the group as part of their internal reporting and assess outstanding receivables for ability to be repaid. Liquidity risk The group's policy is to regularly monitor current and expected liquidity requirements to ensure that it maintains sufficient reserves of cash to meet its liquidity requirements in the short and long term. The Group ordinarily finances its activities through cash generated from operating activities and private and public offerings of equity and debt securities. The table below summarizes the maturity profile of the Group's financial liabilities based on contractual undiscounted payments. 2019 $000 Less than 3 to 12 Total Trade and other payables 579 3,612 4,191 Related party payables 264 330 596 Total 843 3,942 4,787 Foreign currency risks The group operates internationally although the majority of its operations are based in the United Kingdom and the majority of assets and liabilities denominated in British Pounds. It therefore is exposed to foreign exchange risk arising from exposure to various currencies primarily the Euro and US Dollar. Due to the majority of assets being denominated in British Pounds the group has no formal policies for managing foreign currency risks. Interest rate risk The Group has limited exposure to interest-rate risk arising from its bank deposits. These deposit accounts are held at variable interest rates based on Allied Irish Bank base rate. The directors do not consider the impact of possible interest rate changes based on current market conditions to be material to the net result for the year or the equity position at the year-end for the years ended 31 December 2019, 2018 or 2017.

Capital Risk Management

Capital Risk Management	12 Months Ended
	Dec. 31, 2019
Capital Risk Management [Abstract]
CAPITAL RISK MANAGEMENT	23. CAPITAL RISK MANAGEMENT For the purpose of the Group's capital management, capital includes called up share capital, share premium, share based payment reserve for options, convertible loan note reserve, share based payment reserve for warrants, capital reduction reserve and all other equity reserves attributable to the equity holders of the parent as reflected in the statement of financial position. The Group adjusts its capital structure in light of changes in economic conditions and expected business demands on capital. In order to maintain or adjust its capital structure, the Group considers whether or not to pay dividends and adjusts the amount of any dividend payments to shareholders. The Group may also return capital to shareholders or issue additional shares.

Trade and Other Payables

Trade and Other Payables	12 Months Ended
	Dec. 31, 2019
Trade and other payables [abstract]
TRADE AND OTHER PAYABLES	24. TRADE AND OTHER PAYABLES Year ended Group 2019 2018 2017 $000 $000 $000 Trade payables 4,191 3,641 3,738 Accruals 2,206 2,310 683 6,397 5,951 4,421

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related party transactions [abstract]
RELATED PARTY TRANSACTIONS	25. RELATED PARTY TRANSACTIONS Rasna Therapeutics Inc is a related party as Kunwar Shailubhai, director of our Company, is also a director of Rasna. In addition, Tiziano Lazzaretti, CFO of Tiziana, is also CFO of Rasna. Rasna is also party to a Shared Services agreement with Tiziana whereby the Company is charged for shared services such as the payroll and rent. As of December 31, 2019, $5k was owed to Tiziana Life Sciences PLC. OKYO Pharma Ltd is a related party as Kunwar Shailubhai, director of our Company, is also a director of OKYO. In addition, Tiziano Lazzaretti, CFO of Tiziana, is also CFO of OKYO. OKYO is also party to a Shared Services agreement with Tiziana whereby the Company is charged for shared services such as the payroll and rent. As of December 31, 2019, $28k was owed to Tiziana Life Sciences PLC in respect of this agreement. OKYO Pharma Ltd has also extended a short term loan facility of $527k to Tiziana with interest payable of 20% per annum, as Tiziana failed to repay the amount owed by the repayment date. In respect of this loan, $264k was due as of December 31, 2019 and $40k was recognized in the Statement of Comprehensive Income during the year ended December 31, 2019 with regards to the interest accrued on the loan. Gensignia Life Sciences Inc is a related party as Kunwar Shailubhai, director of our Company, is also a director of Gensignia. In addition, Tiziano Lazzaretti, CFO of Tiziana, is also CFO of Gensignia. As of December 31, 2019, $320k was owed to Tiziana Life Sciences PLC. Planwise Group Limited is a related party as Gabriele Cerrone, Executive Chairman, is considered to have a beneficial interest in the shares and voting rights held Planwise Group Limited. As described in Note 19, the Company has a Convertible Debt Instrument outstanding with Planwise and as of December 31, 2019, Tiziana owed $332k (2018: £310k) with respect to this instrument.

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
LEASES	26. LEASES All leases are accounted for by recognising a right-of-use asset and a lease liability except for: ● Leases of low value assets; and ● Leases with a duration of 12 months or less. IFRS16 was adopted 1 January 2019 without restatement of comparative figures. For an explanation of the transitional requirements that were applied as at I January 2019, see Note 4. The following policies apply subsequent to the date of initial application, 1 January 2019. The Group has leases for its offices. Each lease is reflected on the balance sheet as a right-of-use asset and a lease liability. The Group does not have any short term leases or leases of low value assets. Variable lease payments which do not depend on an index or a rate (such as lease payments based on a percentage of Group sales) are excluded from the initial measurement of the lease liability and asset. The Group classifies its right-of-use assets in a consistent manner to its property, plant and equipment (see Note 12). For leases over office buildings and factory premises the Group must keep those properties in a good state of repair and return the properties in their original condition at the end of the lease. During the course of 2019, the Group sublet one of its office spaces. This has been recognised as a writeback of the associated right of use asset and the recognition of a finance lease receivable for the value of the sublease. Right-of-use assets 31 Dec $000 At 1 January 2019 1,098 Additions - Depreciation (256 ) Finance lease receivable (328 ) Loss on disposal (74 ) Foreign exchange movements (6 ) 433 Lease Liabilities 31 Dec $000 At 1 January 2019 1,098 Additions - Interest expense 30 Lease payments (309 ) 820 Lease liabilities are presented in the statement of financial; position as follows: 31 Dec 1 Jan $000 $000 Current 279 260 Non-current 541 839 820 1,098 The lease liabilities are secured by the related underlying assets. Future minimum lease payments as at 31 December 2019 were as follows: Minimum lease payment due Within 1 year 1-2 years 2-5 years Over 5 years Total 31 December 2019 Lease payments 301 274 295 - 870 Finance Charges (22 ) (13 ) (15 ) - (51 ) Net Present Values 279 261 280 820 The total cash outflow for leases in the year to 1 December 2019 was $206,703.

Post Balance Sheet Events - Pos

Post Balance Sheet Events - Post 31 December 2019	12 Months Ended
	Dec. 31, 2019
Post Balance Sheet Events - Post 31 December 2018 [Abstract]
POST BALANCE SHEET EVENTS - POST 31 DECEMBER 2018	27. POST BALANCE SHEET EVENTS – POST 31 DECEMBER 2019 On 13 January 2020, the Company announced that its intention to redomicile the Company to Bermuda and its proposed cancellation from AIM. On 21 January 2020, the Company announced that the appointment of Greg MacRae to the Board of Directors. On 23 January 2020, the Company announced the filing of a Form F-3 with the Securities Exchange Commission to enable the Company to potentially conduct a future fundraise in the US. A General meeting was subsequently called to seek general authorities to issue shares which would be required in the event that the Company were to utilise the shelf registration. On 11 March 2020, the Company announced that it is expediting development of TZLS-501, a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus COVID-19 (SARS-CoV-2). Tiziana plans to administer TZLS-501 using a proprietary formulation technology. The Company entered into a world-wide license for composition-of-matter of TZLS-501, a fully human mAb targeting IL-6R, with Novimmune, SA, a Swiss biotechnology company in January 2017. On 16 March 2020, the Company announced the closing of its underwritten follow-on public offering of American Depositary Shares ("ADSs") on the NASDAQ Global Market. The Company issued 3,333,333 ADSs (representing 16,666,665 new ordinary shares of nominal value £0.03 each in the capital of the Company) at a price to the public of $3.00 per ADS raising gross proceeds of approximately $10 million (before deducting underwriting discount, commissions and offering expenses). Each ADS offered represents five (5) Ordinary Shares (reduced from 10 ordinary shares in a stock split that took place in October 2019. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 499,999 ADSs on the same terms and conditions (the "Option"). All ADSs sold in the Offering were offered by the Company. The number of Ordinary Shares represented by ADSs comprised in the Offering (including by way of the exercise of the Option) were within existing shareholder authorities. On 9 April 2020, the Company announced that it had developed investigational new technology to treat COVID-19 infections, which consists of direct delivery of anti-IL-6 receptor (anti-IL-6R) monoclonal antibodies (mAbs) into the lungs using a handheld inhaler or nebulizer. Development of this novel technology is a step forward toward expediting development of TZLS-501, a fully-human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with COVID-19 (SARS-CoV-2) coronavirus. The Company believes the technology could also be applicable for use with other FDA approved mAbs and drugs. The Company has submitted a provisional patent application for the delivery technology. At this time, an estimate of the financial effect cannot be determined. On 15 April 2020 the Company entered into an "At the Market" or "ATM" Sales Agreement with Think Equity (a division of Fordham Financial Management, Inc.) to raise up to US$20m from the sale of ADSs (each representing 5 new ordinary shares). On 15 April 2020, the Company issued 420,000 new Ordinary Shares of 3 pence each in connection with the exercise of options by a former director granted under the Company's 2014 share option scheme. On 24 April 2020, the Company issued 6,118,797 new Ordinary Shares of 3 pence each in paid in respect of (i) the conversion of £1,595,322 in face value of its outstanding convertible notes at a conversion price of 42 pence per share (including accrued interest of 16 per cent.); and (ii) the exercise of 1,712,672 warrants at a price of 35 pence per share, yielding £599,435.20 in cash proceeds for the Company and retiring £1,595,322 of indebtedness. On 6 May, 2020, the Company held a General Meeting and announced that all resolutions had been passed. The resolutions included the grant of options under the Company's long-term incentive plan or US sub-plan (as appropriate) over 9,000,000 Shares to Dr Kunwar Shailubhai, the Company's Chief Executive Officer and Chief Scientific Officer; (b) options over 400,000 Shares to Tiziano Lazzaretti, the Company's Chief Financial Officer; and (c) options over a further 327,000 Shares to other staff members, all at an exercise price of 35p per share and all conditional on the surrender of all existing share options held by those individuals. The resolutions also included the grant by the Company of options over 3,809,403 Shares to Gabriele Cerrone, the Company's Executive Chairman under the Company's long-term incentive plan at an exercise price of 35p per share and conditional on the surrender of all existing share options held by Mr Cerrone. On 18 May 2020, the Company issued 264,286 ordinary shares of 3 pence each in respect of the exercise of 264,286 warrants at a price of 50 pence per share, yielding £132,143 in cash proceeds for the Company. On 2 June 2020, the Company issued 1,234,399 ordinary shares in respect of the exercise of 1,234,399 warrants at a price of 39 pence and 50 pence per share, yielding £578,700 in cash proceeds for the Company. The Company also announced that during the calendar month of May, the Company issued a total of 1,743,445 ordinary shares under the Company's ATM sales agreement announced on 15 April 2020 to meet sales of a total of 348,689 ADSs under the ATM sales agreement, totalling gross proceeds of $1,985,004. The Company does not believe that the recent outbreak of COVID-19 pandemic will have an adverse effect on the Company' operations. Indeed, the Company has raised substantial funds during the pandemic to enable it to expedite development of TZLS-501 as well as other initiatives within its project pipeline.

Financial Commitments

Financial Commitments	12 Months Ended
	Dec. 31, 2019
Financial Commitments [Abstract]
FINANCIAL COMMITMENTS	28. FINANCIAL COMMITMENTS The Group's main financial commitments relate to the contractual payments in respect of its licensing agreements. Due to the uncertain nature of scientific research and development and the length of time required to reach commercialisation of the products of this research and development, pre-clinical, clinical and commercial milestone obligations are not detailed until there is a reasonable certainty that the obligation will become payable. Contractual commitments are detailed where amounts are known and certain. ● Milciclib project research future payments relate to the achievement of clinical milestones or the payment of royalties. ● Foralumab project – Future payments relate to the achievement of clinical milestones or the payment of royalties. Diligence obligations are payable to BMS/Medarex should the project continue to commercialisation. The Group also has financial commitments with a realisation bonus due to its Executive Chairman. The Executive Chairman is also eligible to receive two realisation bonuses as follows: (c) in the event that, either: (i) the Group raises, in one or a series of transactions, new equity capital in excess of £20,000,000 (after expenses); or (ii) there is a sale, in one or a series of transactions, of all or substantially all of the assets (calculated on the basis of book values) of the Group Companies (or a licence of the same on an exclusive or non-exclusive basis), where the Enterprise Value equals or exceeds £150,000,000; or (iii) there is a change of control where the Enterprise Value equals or exceeds £150,000,000, in which case the Realisation Bonus will be the amount equal to the Enterprise Value multiplied by two and a half (2.5) per cent; (d) In addition to the payment of the Realisation Bonus outlined above, in the event that, during this Agreement, either: (i) there is a sale, in one or a series of transactions, of all or substantially all of the assets ( calculated on the basis of book values) of the Group ( or a licence of the same on an exclusive or non-exclusive basis ), where · the Enterprise Value equals or exceeds £300;000,000; or (ii) there is either a change of control where the Enterprise Value equals or exceeds £300,000,000, the Chairman will be entitled to receive an additional Realisation Bonus in the amount equal to the Enterprise Value multiplied by three and a half (3.5) per cent. The Enterprise Value means: (i) in the case of a change of control resulting in consideration payable to the Group (for example, on a sale of its assets or licensing transaction), the total cash and non-cash consideration received by the Group; or (ii) in the case of a change of control resulting in consideration payable to the shareholders of the ordinary shares in the issued share capital of the Group from time to time, the total cash and non-cash consideration payable to the Shareholders.

Accounting Policies (Policies)

Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of preparation	Basis of preparation The consolidated financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB), and IFRIC interpretations as applicable to companies reporting under IFRS. These accounts have been prepared under the historical cost convention.
Going Concern	Going Concern The Group incurred losses during the year and has net assets at the year end. The Group is in the early stages of developing its business focusing on the discovery and development of novel molecules that treat human disease in oncology and immunology. As the Group is pre-revenue, the Directors expect the Group to incur further losses and to require significant capital expenditure in continuing to develop clinical stage development therapeutic candidates in both oncology and immunology. The Group has successfully funded clinical trials to date and going forward will need to continue to secure additional investment to fund the clinical trials. The Directors have prepared cash flow projections that include the costs associated with the continued clinical trials and additional investment to fund that operation. On the basis of those projections, the directors conclude that the company will be able to meet its liabilities as they fall due for the next 12 months from the date when these financial statements are issued. Until and unless the Group and Company secures sufficient investment to fund their clinical pipeline, there is a material uncertainty about the Group and Company's ability to continue as a going concern after the next 12 months, and therefore about the applicability of the going concern basis of preparation. The financial statements do not include the adjustments that would be required if the going concern basis of preparation was considered inappropriate. The directors do not believe that Brexit will have an impact on the Group's ability to raise funds as it has access to the US market due to its listing on the Nasdaq.
Basis of consolidation	Basis of consolidation Subsidiary undertakings are all entities over which the Group exercises control. The Group has control when it can demonstrate all of the following: (a) power over the investee; (b) exposure, or rights, to variable returns from its involvement with the investee; and (c) the ability to use its power over the investee to affect the amount of the investor's return. The existence and effect of both current voting rights and potential voting rights that are currently exercisable or convertible are considered when assessing whether control of an entity is exercised. Subsidiaries are consolidated from the date at which the Group obtains control and are de-consolidated from the date at which control ceases.
Business combination	Business combination The consolidated position of the Group is as a result of the reverse acquisition of Alexander David Investments plc by Tiziana Pharma Ltd and the subsequent listing of the Company as Tiziana Life Sciences Plc on 24 April 2014. Tiziana Pharma Limited was incorporated on 4 November 2013 and prepared its first set of financial statements to 31 December 2014. Therefore, the parent and subsidiary had the same reporting date but Tiziana Pharma Limited had a long period of account. No adjustment was made in the consolidated financial statements for the difference in length of reporting period because the only transaction in Tiziana Pharma Limited at 31 December 2013 was the issue of ordinary share capital of £1.
Segment reporting	Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the Board. The Board allocates resources to and assess the performance of the segments. The Board considers there to be only one operating segment being the research and development of biotechnological and pharmaceutical products.
Taxation	Taxation The tax expense for the year represents the total of current taxation and deferred taxation. The charge in respect of current taxation is based on the estimated taxable profit for the year. Taxable profit for the year is based on the profit as shown in the income statement, as adjusted for items of income or expenditure which are not deductible or chargeable for tax purposes. The current tax liability for the year is calculated using tax rates which have either been enacted or substantively enacted at the balance sheet date. Deferred tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the balance sheet date and expected to apply when the related deferred tax is realized, or the deferred liability is settled. Deferred tax assets are recognized to the extent that it is probable that the future taxable profit will be available against which the temporary differences can be utilized. Research and Development tax credits are provided for in the year that the costs are incurred. These are estimated based on eligible research and development expenditure. Any difference rebated are recognized in the following year, when the cash is received from the UK tax authorities.
Foreign currency translation	Foreign currency translation Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the entity operates (the functional currency). The consolidated financial statements are presented in US dollars, which is the Group's presentation currency. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the income statement. The financial statements of overseas subsidiary undertakings are translated into US dollars on the following basis: ● Assets and liabilities at the rate of exchange ruling at the year-end date. ● Profit and loss account items at the average rate of exchange for the year. Exchange differences arising from the translation of the net investment in foreign entities, borrowings and other currency instruments designated as hedges of such investments, are taken to equity (and recognized in the statement of comprehensive income) on consolidation.
License fees	License fees Payments related to the acquisition of rights to a product or technology are capitalised as intangible assets if it is probable that future economic benefits from the asset will flow to the entity and the cost of the asset can be reliably measured. Payments made which provide the right to perform research are carefully evaluated to determine whether such payments are to fund research or acquire an asset. Licence fees expenses are recognised as incurred.
Research and development	Research and development All on-going research and development expenditure is currently expensed in the period in which it is incurred. Due to the regulatory environment inherent in the development of the Group's products, the criteria for development costs to be recognised as an asset, as set out in IAS 38 'Intangible Assets', are not met until a product has been granted regulatory approval and it is probable that future economic benefit will flow to the Group. The Group currently has no qualifying expenditure.
Financial instruments	Financial instruments The Group classifies a financial instrument, or its component parts, as a financial liability, a financial asset or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument. The Group evaluates the terms of the financial instrument to determine whether it contains an asset, a liability or an equity component. Such components shall be classified separately as financial assets, financial liabilities or equity instruments. A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. (a) Financial assets, initial recognition and measurement and subsequent measurement All financial assets not recorded at fair value through profit or loss, such as receivables and deposits, are recognized initially at fair value plus transaction costs. Financial assets carried at fair value through profit or loss are initially recognized at fair value, and transaction costs are expensed in the income statement. The measurement of financial assets depends on their classification. Financial assets such as receivables and deposits are subsequently measured at amortized cost using the effective interest method, less loss allowance. The Group does not hold any financial assets at fair value through profit or loss or fair value through other comprehensive income. (b) Financial liabilities, initial recognition and measurement and subsequent measurement Financial liabilities are classified as measured at amortized cost or FVTPL. A financial liability is classified as at FVTPL if it is a derivative. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognized in profit or loss. Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss. The Group's financial liabilities include trade and other payables. Warrants Warrants issued by the Group to investors as part of a share subscription are compound financial instruments where the warrant meets the definition of a financial liability. The financial liability component is initially measured at fair value in the Consolidated Statement of Financial Position. Equity is measured at the residual between the subscription price for the entire instrument and the liability component. The financial liability component is remeasured depending on its classification. Equity is not remeasured.
Investments	Investments Investments are held as non-current assets and comprise investments in subsidiary undertakings and are stated at cost less provision for any impairment.
Share capital	Share capital Ordinary shares of the Company are classified as equity.
Property, plant and equipment	Property, plant and equipment (i Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses. Costs include expenditures that are directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalised as part of that equipment. When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses on disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment, and are recognised in profit or loss. (ii) Depreciation Depreciation is calculated on the depreciable amount, which is the cost of an asset, or other amount substituted for cost, less its residual value. Depreciation is recognised in profit or loss on a straight-line basis over the estimated useful life of each part of an item of property, plant and equipment. Leased assets are depreciated over the shorter of the lease term and their useful lives unless it is reasonably certain that the Company will obtain ownership by the end of the lease term. The estimated useful lives for the current period and the comparative period are as follows. Fixtures and fittings 5 years IT and equipment 3 years Depreciation methods, useful lives and residual values are reviewed at each reporting date. Depreciation is allocated to the operating expenses line of the income statement.
Impairment	Impairment Impairment of financial assets measured at amortised cost At each reporting date the Group recognises a loss allowance for expected credit losses on financial assets measured at amortised cost. In establishing the appropriate amount of loss allowance to be recognised, the Group applies either the general approach or the simplified approach, depending on the nature of the underlying group of financial assets. General approach The general approach is applied to the impairment assessment of refundable lease deposits and other refundable lease contributions, restricted cash and cash and cash equivalents. Under the general approach the Group recognises a loss allowance for a financial asset at an amount equal to the 12-month expected credit losses, unless the credit risk on the financial asset has increased significantly since initial recognition, in which case a loss allowance is recognised at an amount equal to the lifetime expected credit losses. Simplified approach The simplified approach is applied to the impairment assessment of trade receivables. Under the simplified approach the Group always recognises a loss allowance for a financial asset at an amount equal to the lifetime expected credit losses. Non-financial assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. Non-financial assets are impaired when its carrying amount exceed its recoverable amount. The recoverable amount is measured as the higher of fair value less cost of disposal and value in use. The value in use is calculated as being net projected cash flows based on financial forecasts discounted back to present value.
Leases	Leases IFRS 16 Leases was issued in January 2016 and was implemented by the Group from 1 January 2019. The Standard replaces IAS 17 and requires lease liabilities and 'right of use' assets to be recognised on the balance sheet for almost all leases. The adoption methodology of IFRS 16 is the cumulative catch-up method, and the impact of adoption was to recognise a right of use asset of $1,098k and a lease liability of $1,098k on 1 January, 2019.
Fair Value Measurement	Fair Value Measurement Management have assessed the categorisation of the fair value measurements using the IFRS 13 fair value hierarchy. Categorisation within the hierarchy has been determined on the basis of the lowest level of input that is significant to the fair value measurement of the relevant asset as follows; Level 1 - valued using quoted prices in active markets for identical assets Level 2 - valued by reference to valuation techniques using observable inputs other than quoted prices included within Level 1; Level 3 - valued by reference to valuation techniques using inputs that are not based on observable market data.
Share based payments	Share based payments The calculation of the fair value of equity-settled share based awards and the resulting charge to the statement of comprehensive income requires assumptions to be made regarding future events and market conditions. These assumptions include the future volatility of the Company's share price. These assumptions are then applied to a recognised valuation model in order to calculate the fair value of the awards. Where employees, directors or advisers are rewarded using share based payments, the fair value of the employees', directors' or advisers' services are determined by reference to the fair value of the share options/warrants awarded. Their value is appraised at the date of grant and excludes the impact of any nonmarket vesting conditions (for example, profitability and sales growth targets). Warrants issued in association with the issue of Convertible Loan Notes are also considered as share based payments and a share based payment charge is calculated for these too. In accordance with IFRS 2, a charge is made to the statement of comprehensive income for all share-based payments including share options based upon the fair value of the instrument used. A corresponding credit is made to a share based payment reserve - options, in the case of options/warrants awarded to employees, directors, advisers and other consultants. If vesting periods or other vesting conditions apply, the expense is allocated over the vesting period, based on the best available estimate of the number of share options/warrants expected to vest. Non market vesting conditions are included in assumptions about the number of options / warrants that are expected to become exercisable. Estimates are subsequently revised, if there is any indication that the number of share options/warrants expected to vest differs from previous estimates. No adjustment is made to the expense or share issue cost recognised in prior periods if fewer share options ultimately are exercised than originally estimated. Upon exercise of share options/warrants, the proceeds received are allocated to share capital with any excess being recorded as share premium. Where share options are cancelled, this is treated as an acceleration of the vesting period of the options. The amount that otherwise would have been recognised for services received over the remainder of the vesting period is recognised immediately within the Statement of Comprehensive Income. All goods and services received in exchange for the grant of any share based payment are measured at their fair value.
Convertible loan notes	Convertible loan notes Where there is no option to repay in cash or the Company has the choice of settlement, and the interest rate is fixed The Group considers these to be convertible equity instruments and records the principal of the loan note as an equity in a Convertible loan note reserve. The accrued interest on the principal amount, for which there is no obligation to settle in cash, is also recorded in the Convertible loan note reserve. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from the convertible loan note reserve to share capital and share premium. Where the above conditions are not met The Group considers these to be convertible debt instruments and records the principal of the loan note as a debt liability in the liabilities section of the statement of financial position. The accrued interest on the principal amount is recorded in the income statement and as an increase in the debt liability. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from the debt liability to share capital and share premium. Under IAS 32 the liability and equity components of convertible loan notes must be presented separately on the statement of financial position. The Group has examined the terms of each issue of convertible loan notes and determined their accounting treatment accordingly. Convertible loan notes are treated differently depending upon a number of factors.

Accounting Policies (Tables)

Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Schedule of estimated useful lives for the current period and the comparative period	Fixtures and fittings 5 years IT and equipment 3 years

Changes in Accouting Policies_2

Changes in Accouting Policies and Prior Year Adjustments (Tables)	12 Months Ended
	Dec. 31, 2019
Changes in Accouting Policies and Prior Year Adjustments [Abstract]
Schedule of operating lease liabilities and lease payments	2019 $000 Operating lease commitments disclosed under IAS17 as at 31 December 2018 1,142 Remaining lease commitments discounted using the Group's incremental borrowing rate as at the date of initial application 1,098 Lease Liability recognised as at 1 January 2019 1,098 Of which: Current lease liabilities 260 Non-current lease liabilities 839
Schedule of right-of-use assets	31 December 1 January $000 $000 Properties 433 1,098 Total right-of-use assets 433 1,098
Schedule of adjustments impacted prior period of impact on financial statements	1 January Adjustment 1 January $'000 $'000 $'000 Consolidated Balance Sheet (Extract) Convertible loan note reserve 17,158 (374 ) (16,784 ) Share based payment reserve (warrants) 271 648 919 Retained Earnings (29,726 ) (274 ) (30,000 ) Total Equity 4,0883 - 4,088 ) 31 December Adjustment 31 December $'000 $'000 $'000 Consolidated Balance Sheet (Extract) Share Premium 31,284 (725 ) 30,559 Share based payment reserve (warrants) 579 885 1,464 Translation reserve 1997 (9 ) 1,988 Retained Earnings (42,613 ) (151 ) (42,764 ) Total Equity (2,278 ) - (2,278 ) 31 December Adjustment 31 December $'000 $'000 $'000 Consolidated Balance Sheet (Extract) Share Premium 40,862 (1,030 ) 39,832 Share based payment reserve (warrants) 743 1,131 1,874 Translation reserve 1977 (91 ) 1,967 Retained Earnings 50,630 ) (10 ) (50,721 ) Total Equity 519 - 519 31 December Adjustment 31 December $'000 $'000 $'000 Consolidated Statement of Comprehensive Income (Extract) Operating Expenses (4,418 ) 60 (4,358 ) Loss before taxation (9,939 ) 60 (9,879 )

Operating Loss (Tables)

Operating Loss (Tables)	12 Months Ended
	Dec. 31, 2019
Operating Loss [Abstract]
Schedule of operating loss	Year Ended 2019 2018 2016 License fee 553 662 662 Depreciation of Property, Plant and Equipment 5 13 13 Depreciation (Right-of-use asset) 245 Foreign exchange (gain)/losses 165 45 45 967 720 720

Employees (Tables)

Employees (Tables)	12 Months Ended
	Dec. 31, 2019
Employees [Abstract]
Schedule of employees	Year ended 2019 $'000 2018 2017 Group Staff costs comprised: Directors' salaries (including bonus) 1,145 606 457 Employee's wages, salaries and bonus 696 712 861 Social security costs 609 491 491 Share based payment charge 1,266 539 539 3,716 2,348 2,348 The average monthly number of employees, including directors, employed by the group during the year was: Research and Development 5 6 6 Corporate and administration 4 5 5 9 11 11

Remuneration of Key Managemen_2

Remuneration of Key Management Personnel (Tables)	12 Months Ended
	Dec. 31, 2019
Remuneration of Key Management Personnel [Abstract]
Schedule of remuneration of key management personnel	Year ended $'000 2019 2018 2017 Directors Bonus Salary Directors Bonus Salary Directors Salary W Simon 48 - - 51 - - 49 - G. Cerrone (1) 102 182 - 124 - - 86 - R. Dalla-Favera 3 - - 26 - - 26 - K. Shailubhai (2) - 210 600 - 105 300 10 286 153 392 600 201 105 300 171 286 (1) Gabriele Cerrone's bonus covers the period June 9, 2016 to December 31, 2019 (2) Kunwar Shailubhai became an employee of the company on May 24, 2017, at which point he ceased to be a non-executive director.
Schedule of share options were granted to directors	Year ended 2019 2018 2017 Number of options Number of options Number of options G. Cerrone - 550,000 - K. Shailubhai - 6,500,000 400,000 L. Zanbeletti - 550,000 - 7,600,000 400,000

Finance Costs (Tables)

Finance Costs (Tables)	12 Months Ended
	Dec. 31, 2019
Finance Costs [Abstract]
Schedule of finance costs	Year ended 2019 2018 2017 Group Finance Income Finance income received on net investment in lease 1 - - Total finance income 1 - - Finance Expense Finance charge accrued on convertible loan notes 61 12 12 Interest expense on lease liabilities 31 - - Total finance Expense 92 12 12 Total Finance Cost 92 12 12

Taxation (Tables)

Taxation (Tables)	12 Months Ended
	Dec. 31, 2019
Taxation [Abstract]
Schedule of taxation	Year Ended 2019 2018 2017 Group Current year tax (credit) (661 ) (1,067 ) (489 Adjustments due to prior periods (28 ) (879 ) (1,423 ) Total tax (credit) for the period (689 ) (1,945 ) (1,912 ) The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 21.49%. The difference can be reconciled as follows: Loss before taxation (10,013 ) (9,939 ) (10,628 ) Loss charged at standard rate of corporation tax 19 % (2018: 19%; 2017: 19.25%) (1,903 ) (1,888 ) (2,046 ) Other timing differences - 1,104 2,889 Movement in unrecognised deferred tax (241 ) - - Expenses not deductible for taxation 1,727 176 31 Adjustments due to prior periods (28 ) (879 ) (1,423 ) Research and development claim (285 ) (459 ) (1,366 Consolidation adjustment in relation to foreign exchange movements (689 ) - - Other timing differences - - 3 (689 ) (1,945 ) (1,912 )

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2019
Loss Per Share [Abstract]
Schedule of basic loss per share	Year ended 2019 2018 (Restated) 2017 (Loss) attributable to equity holders of the company ($000) (9,323 ) (7,934 ) (8,716 ) Weighted average number of ordinary shares in issue 136,482,627 127,553,866 106,403,903 Basic loss per share (cents per share) (6.83 ) (6.22 ) (8.59 )

Property, IT and Equipment (Tab

Property, IT and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Property IT and Equipment [Abstract]
Schedule of property, IT and equipment	$000 Furniture IT Total Cost At 1 January 2018 15 31 46 Additions - - - Disposals - - - At 31 December 2018 15 31 46 Depreciation At 1 January 2018 3 20 23 Charge in year 6 10 16 At 31 December 2018 9 30 39 Net Book Value as at 31 December 2018 6 1 7 $000 Furniture IT Total Cost At 1 January 2019 15 31 46 Additions - 4 4 Disposals - - - At 31 December 2019 15 35 50 Depreciation At 1 January 2019 9 30 39 Charge in year 3 2 5 At 31 December 2019 12 32 44 Net Book Value as at 31 December 2019 3 3 6

Other Receivables (Tables)

Other Receivables (Tables)	12 Months Ended
	Dec. 31, 2019
Other Receivables [Abstract]
Schedule of other receivables	$000 Year ended 2019 2018 Group Other receivables 134 246 Taxation receivable 676 1,019 Related party receivable 324 25 Prepayments 28 42 Other current assets - 276 1,162 1,609

Finance Lease Receivable (Table

Finance Lease Receivable (Tables)	12 Months Ended
	Dec. 31, 2019
Convertible Equity Instrument [Abstract]
Schedule of classified a finance lease receivable	Finance lease receivable 31 Dec 2019 1 Jan 2019 $000 $000 Current 142 - Non-current 149 - 292 ss -
Schedule of undiscounted lease payments	1 Year 2 years 3 or more years $000 $000 £000 Undiscounted lease payments receivable 149 150 - 149 150 -
Schedule of income from its subleasing activities	Finance Lease Receivable 31 December 2019 $000 Finance Lease receivable as at 1 Nov 2018 327 Sublease income (36 ) 292

Investments in Subsidiaries (Ta

Investments in Subsidiaries (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of subsidiaries [abstract]
Schedule of interest in subsidiary undertakings	Name Principal activity Registered Address Percentage shareholding Country of incorporation Tiziana Pharma Limited Clinical stage biotechnology company 3 rd 100 % England & Wales Tiziana Therapeutics, Inc. Clinical stage biotechnology company 420 Lexington Avenue 100 % USA Longevia Genomics SRL Biotech Discovery Company Via Constantinpoli 42 100 % Italy

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure of classes of share capital [abstract]
Schedule of share capital	2019 2018 2019 2018 2019 2018 Ordinary Shares Deferred Shares $000 In issue at 1 January 136,463,818 125,054,805 - - 8,592 8,141 Issued for cash - 7,742,167 - - - 311 Issued in lieu of consultancy fees 190,698 - - - 7 - Conversion of Convertible Loan notes - - - - - - Conversion of warrants - 1,454,644 - - - 56 Conversion of Loan - 2,137,625 - 82 In lieu of commission - 74,577 - - - 2 In issue at 31 December 136,654,516 136,463,818 - - 8,599 8,592

Share Based Payments (Tables)

Share Based Payments (Tables)	12 Months Ended
	Dec. 31, 2019
Share Based Payments [Abstract]
Schedule of share-based payment arrangements	2019 2018 2017 Weighted Weighted Weighted Average exercise price (cents) Options Average exercise price (cents) Options Average exercise price (cents) Options Outstanding at 1 January 107 18,617 125 10,717 90 12,449 Granted - - 104 9,500 216 668 Forfeited (152 ) (2,238 ) (219 ) (1,600 ) (20 ) (2,400 ) Outstanding at 31 December 113 16,379 107 18,617 125 10,717 Exercisable at 31 December 67 5,521 50 5,236 57 5,011
Schedule of estimated a forfeiture rate of zero	30 April 30 August 2017 10 March Grant date share price $ 1.041 $ 2.156 $ 2.331 Exercise share price $ 1.041 $ 2.156 $ 2.331 Vesting periods Yr1, Yr 2, Yr 3, Yr4 Yr 1, Yr 2, Yr 3, Yr4 Yr1, Yr 2, Yr 3, Yr4 Risk free rate 0.69% to 1.03 % 0.69% to 1.09 % 0.38% to 1.09 % Expected volatility 58% to 60 % 58% to 60 % 80% to 167 % Option life 10 years 10 years 10 years Weighted average share price $ 1.041 $ 2.156 $ 2.331 Weighted average fair value per share option $ 0.484 $ 0.770 $ 1.433

Convertible Debt Instrument (Ta

Convertible Debt Instrument (Tables)	12 Months Ended
	Dec. 31, 2019
Convertible Loan Notes [Abstract]
Schedule of planwise convertible loan note	Year ended 2019 2018 2017 $000 $000 $000 Convertible loan notes issued 302 290 278 Accrued interest 11 11 12 313 302 290

Convertible Instruments Class_2

Convertible Instruments Classified as Equity (Tables)	12 Months Ended
	Dec. 31, 2019
Convertible Equity Instrument [Abstract]
Schedule of convertible loan note reserve	2019 $000 Par value of cConvertible loan notes issued 1,850 Less: Fair value of warrants issued to note holders (545 ) 1,305 Accrued interest 52 1,357

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2019
Financial Instruments [Abstract]
Schedule of financial liabilities based on contractual undiscounted payments	2019 $000 Less than 3 to 12 Total Trade and other payables 579 3,612 4,191 Related party payables 264 330 596 Total 843 3,942 4,787

Trade and Other Payables (Table

Trade and Other Payables (Tables)	12 Months Ended
	Dec. 31, 2019
Trade and other payables [abstract]
Schedule of trade and other payables	Year ended Group 2019 2018 2017 $000 $000 $000 Trade payables 4,191 3,641 3,738 Accruals 2,206 2,310 683 6,397 5,951 4,421

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Schedule of Right-of-use assets	Right-of-use assets 31 Dec $000 At 1 January 2019 1,098 Additions - Depreciation (256 ) Finance lease receivable (328 ) Loss on disposal (74 ) Foreign exchange movements (6 ) 433
Schedule of lease liabilities	Lease Liabilities 31 Dec $000 At 1 January 2019 1,098 Additions - Interest expense 30 Lease payments (309 ) 820
Schedule of lease liabilities in the statement of financial position	31 Dec 1 Jan $000 $000 Current 279 260 Non-current 541 839 820 1,098
Schedule of future minimum lease liability payments	Minimum lease payment due Within 1 year 1-2 years 2-5 years Over 5 years Total 31 December 2019 Lease payments 301 274 295 - 870 Finance Charges (22 ) (13 ) (15 ) - (51 ) Net Present Values 279 261 280 820

Accounting Policies (Details)

Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2019
Fixtures and fittings [Member]
Statement Line Items [Line Items]
Estimated useful lives	5 years
IT and equipment [Member]
Statement Line Items [Line Items]
Estimated useful lives	3 years

Accounting Policies (Details Te

Accounting Policies (Details Textual) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)Segment	Jan. 02, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2014$ / shares
Account Policies (Textual)
Issue of ordinary share capital | $ / shares				$ 1
Number of segment | Segment	1
Right of use asset	$ 433
Lease liability	$ 1,098	$ 1,098

Changes in Accouting Policies_3

Changes in Accouting Policies and Prior Year Adjustments (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Changes in Accouting Policies and Prior Year Adjustments [Abstract]
Operating lease commitments disclosed under IAS17 as at 31 December 2018	$ 1,142
Remaining lease commitments discounted using the Group’s incremental borrowing rate as at the date of initial application	1,098
Lease Liability recognised as at 1 January 2019	1,098	$ 1,098
Current lease liabilities	279	260
Non-current lease liabilities	$ 541	$ 839

Changes in Accouting Policies_4

Changes in Accouting Policies and Prior Year Adjustments (Details 1) £ in Thousands, $ in Thousands	Dec. 31, 2019USD ($)	Dec. 31, 2019GBP (£)	Jan. 02, 2019GBP (£)	Dec. 31, 2018USD ($)
Statement Line Items [Line Items]
Total right-of-use assets | $	$ 433
GBP [Member]
Statement Line Items [Line Items]
Properties		£ 433	£ 1,098
Total right-of-use assets		£ 433	£ 1,098

Changes in Accouting Policies_5

Changes in Accouting Policies and Prior Year Adjustments (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Jan. 02, 2017	Dec. 31, 2016
Consolidated Balance Sheet (Extract)
Share Premium	$ 39,931	$ 39,832
Share based payment reserve (warrants)	2,419	1,874
Retained Earnings	(60,044)	(50,721)
Total Equity	(5,514)	519	$ (2,278)		$ 4,088
Consolidated Statement of Comprehensive Income (Extract)
Loss before taxation	$ (10,012)	(9,879)	(10,505)
Previously Reported [Member]
Consolidated Balance Sheet (Extract)
Convertible loan note reserve				$ 17,158
Share Premium		40,862	31,284
Share based payment reserve (warrants)		743	579	271
Translation reserve		1,977	1,997
Retained Earnings		(50,630)	(42,613)	(29,726)
Total Equity		519	(2,278)	(40,883)
Consolidated Statement of Comprehensive Income (Extract)
Operating Expenses		(4,418)
Loss before taxation		(9,939)
Adjustment [Member]
Consolidated Balance Sheet (Extract)
Convertible loan note reserve				(374)
Share Premium		(1,030)	(725)
Share based payment reserve (warrants)		1,131	885	648
Translation reserve		(91)	(9)
Retained Earnings		(10)	(151)	(274)
Total Equity
Consolidated Statement of Comprehensive Income (Extract)
Operating Expenses		60
Loss before taxation		60
Restated [Member]
Consolidated Balance Sheet (Extract)
Convertible loan note reserve				(16,784)
Share Premium		39,832	30,559
Share based payment reserve (warrants)		1,874	1,464	919
Translation reserve		1,967	1,988
Retained Earnings		(50,721)	(42,764)	(30,000)
Total Equity		519	$ (2,278)	$ (4,088)
Consolidated Statement of Comprehensive Income (Extract)
Operating Expenses		(4,358)
Loss before taxation		$ (9,879)

Changes in Accouting Policies_6

Changes in Accouting Policies and Prior Year Adjustments (Details Textual)	Jan. 02, 2019
Changes in Accouting Policies and Prior Year Adjustments (Textual)
Weighted average lessee’s incremental borrowing rate	3.35%

Operating Loss (Details)

Operating Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating Loss [Abstract]
License fee	$ 553	$ 662	$ 662
Depreciation of Property, Plant and Equipment	5	13	13
Depreciation (Right-of-use asset)	245
Foreign exchange (gain)/losses	165	(296)	45
Operating Loss	$ 967	$ 720	$ 720

Employees (Details)

Employees (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Staff costs comprised:
Directors' salaries	$ 1,145	$ 606	$ 457
Employee’s wages, salaries and bonus	696	712	861
Social security costs	609	491	491
Share based payment charge	1,266	539	539
Employees, total	3,716	2,348	2,348
The average monthly number of employees, including directors, employed by the group during the year was:
Research and Development	5	6	6
Corporate and administration	4	5	5
Total	$ 9	$ 11	$ 11

Remuneration of Key Managemen_3

Remuneration of Key Management Personnel (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule of remuneration of key management personnel [Abstract]
Directors fees		$ 153	$ 201	$ 171
Bonus		392	105
Salary		600	300	286
W Simon [Member]
Schedule of remuneration of key management personnel [Abstract]
Directors fees		48	51	49
Bonus
Salary
G. Cerrone [Member]
Schedule of remuneration of key management personnel [Abstract]
Directors fees	[1]	102	124	86
Bonus	[1]	182
Salary	[1]
R. Dalla-Favera [Member]
Schedule of remuneration of key management personnel [Abstract]
Directors fees		3	26	26
Bonus
Salary
K. Shailubhai [Member]
Schedule of remuneration of key management personnel [Abstract]
Directors fees	[2]			10
Bonus	[2]	210	105
Salary	[2]	$ 600	$ 300	$ 286
[1]	Gabriele Cerrone's bonus covers the period June 9, 2016 to December 31, 2019
[2]	Kunwar Shailubhai became an employee of the company on May 24, 2017, at which point he ceased to be a non-executive director.

Remuneration of Key Managemen_4

Remuneration of Key Management Personnel (Details 1) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Schedule of share options were granted to directors [Abstract]
Number of share options		7,600,000	400,000
G. Cerrone [Member]
Schedule of share options were granted to directors [Abstract]
Number of share options		550,000
K. Shailubhai [Member]
Schedule of share options were granted to directors [Abstract]
Number of share options		6,500,000	400,000
L. Zanbeletti [Member]
Schedule of share options were granted to directors [Abstract]
Number of share options		550,000

Remuneration of Key Managemen_5

Remuneration of Key Management Personnel (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Remuneration of Key Management Personnel (Textual)
Payments to a defined contribution pension schemes on behalf of directors or employees	$ 15
Directors or Employees [Member]
Remuneration of Key Management Personnel (Textual)
Payments to a defined contribution pension schemes on behalf of directors or employees		$ 17	$ 6

Finance Costs (Details)

Finance Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Finance Income
Finance income received on net investment in lease	$ 1
Total finance income	1
Finance Expense
Finance charge accrued on convertible loan notes	61	12	12
Interest expense on lease liabilities	31
Total finance Expense	92	12	12
Total Finance Cost	$ 92	$ 12	$ 12

Taxation (Details)

Taxation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Taxation [Abstract]
Current year tax (credit)	$ (661)	$ (1,067)	$ (489)
Adjustments due to prior periods	(28)	(879)	(1,423)
Total tax (credit) for the period	(689)	(1,945)	(1,912)
The tax charge for the year is different from the standard rate of corporation tax in the United Kingdom of 21.49%. The difference can be reconciled as follows:
Loss before taxation	(10,012)	(9,879)	(10,505)
Loss charged at standard rate of corporation tax 19 % (2018: 19%; 2017: 19.25%)	(1,903)	(1,888)	(2,046)
Other timing differences		1,104	2,889
Movement in unrecognised deferred tax	(241)
Expenses not deductible for taxation	1,727	176	31
Adjustments due to prior periods	(28)	(879)	(1,423)
Research and development claim	(285)	(459)	(1,366)
Consolidation adjustment in relation to foreign exchange movements	(689)
Other timing differences			3
Income tax expense (benefit)	$ (689)	$ (1,945)	$ (1,912)

Taxation (Details Textual)

Taxation (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Taxation (Textual)
Standard rate of corporation tax	19.00%	19.00%	19.25%
Maximum percentage of surrenderable losses	14.50%
Term of R&D tax relief claims	2 years
Amount of tax losses	$ 3,517	$ 3,928	$ 4,738
United Kingdom [Member]
Taxation (Textual)
Standard rate of corporation tax	21.49%

Loss Per Share (Details)

Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Loss Per Share [Abstract]
(Loss) attributable to equity holders of the company ($000)	$ (9,323)	$ (7,934)	$ (8,716)
Weighted average number of ordinary shares in issue	136,482,627	127,553,866	106,403,903
Basic loss per share (cents per share)	$ (6.83)	$ (6.22)	$ (8.59)

Property, IT and Equipment (Det

Property, IT and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cost
Beginning	$ 46	$ 46
Additions	4
Disposals
Ending	50	46
Depreciation
Beginning	39	23
Charge in year	5	16
Ending	44	39
Net Book Value	6	7
Furnitures and fixtures [Member]
Cost
Beginning	15	15
Additions
Disposals
Ending	15	15
Depreciation
Beginning	9	3
Charge in year	3	6
Ending	12	9
Net Book Value	3	6
IT equipment [Member]
Cost
Beginning	31	31
Additions	4
Disposals
Ending	35	31
Depreciation
Beginning	30	20
Charge in year	2	10
Ending	32	30
Net Book Value	$ 3	$ 1

Other Receivables (Details)

Other Receivables (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Group
Other receivables	$ 134	$ 246
Taxation receivable	676	1,019
Related party receivable	322	24
Prepayments	28	42
Other current assets		276
Total	$ 1,162	$ 1,069

Other Assets (Details)

Other Assets (Details) - Jun. 30, 2016 € in Thousands, £ in Thousands, $ in Thousands	USD ($)	EUR (€)	GBP (£)
Other Assets (Textual)
Purchase of data repository of DNA, approximately | $	$ 268
Euro [Member]
Other Assets (Textual)
Purchase of data repository of DNA | €		€ 258
GBP [Member]
Other Assets (Textual)
Purchase of data repository of DNA, approximately | £			£ 217

Finance Lease Receivable (Detai

Finance Lease Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 02, 2019
Convertible Equity Instrument [Abstract]
Current	$ 142
Non-current	149
Finance lease receivable total	$ 292

Finance Lease Receivable (Det_2

Finance Lease Receivable (Details 1) - GBP [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017GBP (£)
Statement Line Items [Line Items]
Undiscounted lease payments receivable	$ 149	$ 150
Total	$ 149	$ 150

Finance Lease Receivable (Det_3

Finance Lease Receivable (Details 2) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Convertible Equity Instrument [Abstract]
Finance Lease receivable as at 1 Nov 2018	$ 327
Sublease income	(36)
Total	$ 292

Investments in Subsidiaries (De

Investments in Subsidiaries (Details)	12 Months Ended
	Dec. 31, 2019
Tiziana Pharma Limited [Member]
IfrsDisclosureOfSignificantInvestmentsInSubsidiariesLineItems [Line Items]
Name	Tiziana Pharma Limited
Principal activity	Clinical stage biotechnology company
Registered Address	3rd Floor, 11-12 St James’s Square, London, SW1Y 4LB
Percentage shareholding	100.00%
Country of incorporation	England & Wales
Tiziana Therapeutics Inc [Member]
IfrsDisclosureOfSignificantInvestmentsInSubsidiariesLineItems [Line Items]
Name	Tiziana Therapeutics, Inc.
Principal activity	Clinical stage biotechnology company
Registered Address	420 Lexington Avenue Suite 2525 New York, NY 10170
Percentage shareholding	100.00%
Country of incorporation	USA
Longevia Genomics SRL [Member]
IfrsDisclosureOfSignificantInvestmentsInSubsidiariesLineItems [Line Items]
Name	Longevia Genomics SRL
Principal activity	Biotech Discovery Company
Registered Address	Via Constantinpoli 42 09100-Cagliari (CA)
Percentage shareholding	100.00%
Country of incorporation	Italy

Share Capital (Details)

Share Capital (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Nov. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Schedule of share capital [Abstract]
In issue at 31 December	190,968
In issue at 1 January		$ 8,592	$ 8,141
Issued for cash			311
Issued in lieu of consultancy fees		7
Conversion of Convertible Loan notes
Conversion of warrants			56
Conversion of Loan			82
In lieu of commission			2
In issue at 31 December		$ 8,599	$ 8,592
Ordinary Shares [Member]
Schedule of share capital [Abstract]
In issue at 1 January		136,463,818	125,054,805
Issued for cash			7,742,167
Issued in lieu of consultancy fees		190,698
Conversion of Convertible Loan notes
Conversion of warrants			1,454,644
Conversion of Loan			2,137,625
In lieu of commission			74,577
In issue at 31 December		136,654,516	136,463,818
Deferred Shares [Member]
Schedule of share capital [Abstract]
In issue at 1 January
Issued for cash
Issued in lieu of consultancy fees
Conversion of Convertible Loan notes
Conversion of warrants
In lieu of commission
In issue at 31 December

Share Capital (Details Textual)

Share Capital (Details Textual) £ / shares in Units, $ / shares in Units, £ in Thousands, $ in Thousands	1 Months Ended	12 Months Ended
	Nov. 30, 2019GBP (£)shares	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2019£ / shares	Dec. 31, 2014$ / shares
Share Capital (Textual)
Ordinary shares par value | $ / shares					$ 1
Ordinary shares issued | shares	190,968
Issued in lieu of a consultancy fee | $		$ 7
GBP [Member]
Share Capital (Textual)
Ordinary shares par value | £ / shares				£ 0.03
Issued in lieu of a consultancy fee | £	£ 82,000

Share Based Payments (Details)

Share Based Payments (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Weighted Average exercise price (cents)
Outstanding at 1 January	$ 107	$ 125	$ 90
Granted		104	216
Forfeited	(152)	(219)	(20)
Outstanding at 31 December	113	107	125
Exercisable at 31 December	$ 67	$ 50	$ 57
Options ('000)
Outstanding at 1 January	18,617	10,717	12,449
Granted		9,500	668
Forfeited	(2,238)	(1,600)	(2,400)
Outstanding at 31 December	16,379	18,617	10,717
Exercisable at 31 December	5,521	5,236	5,011

Share Based Payments (Details 1

Share Based Payments (Details 1)	12 Months Ended
	Dec. 31, 2019$ / shares
30 April 2018 [Member]
Statement Line Items [Line Items]
Grant date share price	$ 1.041
Exercise share price	$ 1.041
Vesting periods	Yr1, Yr 2, Yr 3, Yr4
Option life	10 years
Weighted average share price	$ 1.041
Weighted average fair value per share option	$ 0.484
30 April 2018 [Member] | Bottom of range [member]
Statement Line Items [Line Items]
Risk free rate	0.69%
Expected volatility	58.00%
30 April 2018 [Member] | Top of range [member]
Statement Line Items [Line Items]
Risk free rate	1.03%
Expected volatility	60.00%
30 August 2017 [Member]
Statement Line Items [Line Items]
Grant date share price	$ 2.156
Exercise share price	$ 2.156
Vesting periods	Yr 1, Yr 2, Yr 3, Yr4
Option life	10 years
Weighted average share price	$ 2.156
Weighted average fair value per share option	$ 0.770
30 August 2017 [Member] | Bottom of range [member]
Statement Line Items [Line Items]
Risk free rate	0.69%
Expected volatility	58.00%
30 August 2017 [Member] | Top of range [member]
Statement Line Items [Line Items]
Risk free rate	1.09%
Expected volatility	60.00%
10 March 2017 [Member]
Statement Line Items [Line Items]
Grant date share price	$ 2.331
Exercise share price	$ 2.331
Vesting periods	Yr1, Yr 2, Yr 3, Yr4
Option life	10 years
Weighted average share price	$ 2.331
Weighted average fair value per share option	$ 1.433
10 March 2017 [Member] | Bottom of range [member]
Statement Line Items [Line Items]
Risk free rate	0.38%
Expected volatility	80.00%
10 March 2017 [Member] | Top of range [member]
Statement Line Items [Line Items]
Risk free rate	1.09%
Expected volatility	167.00%

Share Based Payments (Details T

Share Based Payments (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands

1 Months Ended

12 Months Ended

Oct. 31, 2019

Nov. 28, 2018

Apr. 19, 2018

Mar. 05, 2018

Jan. 22, 2018

Jan. 16, 2018

Dec. 15, 2017

Dec. 11, 2017

Nov. 11, 2017

May 31, 2015

Mar. 02, 2015

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Share Based Payments (Textual)

Fair value of the share option instruments

$ 5,011

$ 6,591

$ 6,217

Share-based payment

$ 59

Expected term of the awards

15 years

Warrant One [Member]

Share Based Payments (Textual)

Warrant granted

600,000

Exercise price of warrant

$ 0.74

Exercisable warrant

Dec. 31, 2021

Warrant Two [Member]

Share Based Payments (Textual)

Warrant granted

292,500

Exercise price of warrant

$ 0.97

Exercisable warrant

May 31, 2022

Warrant Three [Member]

Share Based Payments (Textual)

Warrant granted

100,000

Exercise price of warrant

$ 2.16

Exercisable warrant

Nov. 20, 2022

Warrant Four [Member]

Share Based Payments (Textual)

Warrant granted

183,333

Exercise price of warrant

$ 2.16

Exercisable warrant

Dec. 11, 2023

Warrant Five [Member]

Share Based Payments (Textual)

Warrant granted

196,667

Exercise price of warrant

$ 2.16

Exercisable warrant

Dec. 15, 2023

Warrant Six [Member]

Share Based Payments (Textual)

Warrant granted

63,334

Exercise price of warrant

$ 2.046

Exercisable warrant

Jan. 15, 2024

Warrant Seven [Member]

Share Based Payments (Textual)

Warrant granted

133,333

Exercise price of warrant

$ 2.04

Exercisable warrant

Jan. 22, 2024

Warrant Eight [Member]

Share Based Payments (Textual)

Warrant granted

78,000

Exercise price of warrant

$ 2.04

Exercisable warrant

Mar. 5, 2024

Warrant Nine [Member]

Share Based Payments (Textual)

Warrant granted

51,563

Exercise price of warrant

$ 1.02

Exercisable warrant

Apr. 19, 2024

Warrant Ten [Member]

Share Based Payments (Textual)

Warrant granted

185,000

Exercise price of warrant

$ 1.02

Exercisable warrant

Nov. 27, 2023

Warrant Thirteen [Member]

Share Based Payments (Textual)

Warrant granted

150,000

Exercise price of warrant

$ 1.02

Exercisable warrant

Nov. 27, 2023

Warrant Eleven [Member]

Share Based Payments (Textual)

Warrant granted

185,950

Exercise price of warrant

$ 0.55

Exercisable warrant

Oct. 31, 2024

Warrant Twelve [Member]

Share Based Payments (Textual)

Warrant granted

1,289,372

Exercise price of warrant

$ 0.55

Exercisable warrant

Oct. 31, 2024

Convertible Debt Instrument (De

Convertible Debt Instrument (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Convertible Loan Notes [Abstract]
Convertible loan notes issued	$ 302	$ 290	$ 278
Accrued interest	11	11	12
Planwise Convertible Loan Note	$ 313	$ 301	$ 290

Convertible Debt Instrument (_2

Convertible Debt Instrument (Details Textual)	12 Months Ended
	Dec. 31, 2019
Convertible Debt Instrument (Textual)
Description of convertible loan notes	From the date of the reverse acquisition a convertible loan note of $247k was in existence as detailed in the Admission Document dated 31 March 2014. Proceeds of the subscriptions for the notes are to be used exclusively to finance the company's on-going working capital requirements. The terms of the loan note are that the loan notes, plus accrued interest at a rate of 4 per cent above Bank of England base rate per annum, will convert into ordinary shares in the company at a price of £0.10 per share at the election of Planwise any time after the second anniversary of the readmission to AIM on 24 April 2014.

Convertible Instruments Class_3

Convertible Instruments Classified as Equity (Details) $ in Thousands	Dec. 31, 2019USD ($)
Convertible Equity Instrument [Abstract]
Par value of cConvertible loan notes issued	$ 1,850
Less: Fair value of warrants issued to note holders	(545)
Total convertible loan notes issued	1,305
Accrued interest	52
Total	$ 1,357

Convertible Instruments Class_4

Convertible Instruments Classified as Equity (Details Textual)	1 Months Ended
	Oct. 31, 2019$ / shares
Convertible Equity Instrument [Abstract]
Convertible equity instrument, description	The Company decided to raise convertible equity finance from supportive existing shareholders. $1,850,000 was raised from the issuance of Convertible Loan Notes. The Loan Notes are short term instruments and carry a coupon of 16% per annum and are convertible (together with all accrued interest) into ordinary shares of nominal value £0.03 each in the capital of the Company at a conversion price of $0.42p, they are not convertible into cash.
Conversion share price	$ 0.42
Warrants exercised period	5 years

Reserves (Details)

Reserves (Details) £ in Thousands	12 Months Ended
	Dec. 31, 2019GBP (£)
GBP [Member]
Reserves (Textual)
Capital reduction reserve	£ 31,100

Financial Instruments (Details)

Financial Instruments (Details) $ in Thousands	Dec. 31, 2019USD ($)
IfrsFinancialInstrumentsItemsLineItems [Line Items]
Trade and other payables	$ 4,191
Related party payables	596
Total	4,787
Less then 3 months [Member]
IfrsFinancialInstrumentsItemsLineItems [Line Items]
Trade and other payables	579
Related party payables	264
Total	843
3 to 12 Months [Member]
IfrsFinancialInstrumentsItemsLineItems [Line Items]
Trade and other payables	3,612
Related party payables	330
Total	$ 3,942

Trade and Other Payables (Detai

Trade and Other Payables (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Trade and other payables [abstract]
Trade payables	$ 4,191	$ 3,641	$ 3,738
Accruals	2,206	2,310	683
Total	$ 6,397	$ 5,951	$ 4,421

Leases (Details)

Leases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
At 1 January 2019	$ 1,098
Additions
Depreciation	(256)
Finance lease receivable	(328)
Loss on disposal	(74)
Foreign exchange movements	(6)
At 31 December 2019	$ 433

Leases (Details 1)

Leases (Details 1) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
At 1 January 2019	$ 1,098
Additions
Interest expense	30
Lease payments	(309)
At 31 December 2019	$ 820

Leases (Details 2)

Leases (Details 2) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Leases [Abstract]
Curent	$ 279	$ 260
Non-current	541	839
Total lease liablilities	$ 820	$ 1,098

Leases (Details 3)

Leases (Details 3) $ in Thousands	Dec. 31, 2019USD ($)
Statement Line Items [Line Items]
Lease payments	$ 870
Finance Charges	(51)
Net Present Values	820
Within 1 year [Member]
Statement Line Items [Line Items]
Lease payments	301
Finance Charges	(22)
Net Present Values	279
1-2 years [Member]
Statement Line Items [Line Items]
Lease payments	274
Finance Charges	(13)
Net Present Values	261
2-5 years [Member]
Statement Line Items [Line Items]
Lease payments	295
Finance Charges	(15)
Net Present Values	280
Over 5 years [Member]
Statement Line Items [Line Items]
Lease payments
Finance Charges
Net Present Values

Leases (Details Textual)

Leases (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Leases (Textual)
Cash outflow	$ 206,703

Related Party Transactions (Det

Related Party Transactions (Details) $ in Thousands	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Statement Line Items [Line Items]
Amounts payable to related party	$ 594	$ 447
Planwise Group Limited [Member]
Statement Line Items [Line Items]
Convertible debt Instrument outstanding	332	$ 310
OKYO Pharma Ltd [Member]
Statement Line Items [Line Items]
Payroll and rent charged	28
Short trem loan facility	$ 527
Interest payable, percentage	0.20
Due to related party	$ 264
Interest accrued on the loan	40
Rasna Therapeutics Inc [Member]
Statement Line Items [Line Items]
Payroll and rent charged	5
Gensignia Lifesceinecs Inc [Member]
Statement Line Items [Line Items]
Payroll and rent charged	$ 320

Post Balance Sheet Events _ Pos

Post Balance Sheet Events – Post 31 December 2019 (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 02, 2020	May 18, 2020	May 06, 2020	Apr. 24, 2020	Apr. 15, 2020	Mar. 16, 2020
Post Balance Sheet Events – Post 31 December 2018 (Textual)
Ordinnary shares	1,234,399	264,286		6,118,797	420,000
Ordinary shares, description	The Company issued 1,234,399 ordinary shares in respect of the exercise of 1,234,399 warrants at a price of 39 pence and 50 pence per share, yielding £578,700 in cash proceeds for the Company.	The Company issued 264,286 ordinary shares of 3 pence each in respect of the exercise of 264,286 warrants at a price of 50 pence per share, yielding £132,143 in cash proceeds for the Company.			The Company issued 420,000 new Ordinary Shares of 3 pence each in connection with the exercise of options by a former director granted under the Company's 2014 share option scheme.
Sales Agreement. description			The Company held a General Meeting and announced that all resolutions had been passed. The resolutions included the grant of options under the Company's long-term incentive plan or US sub-plan (as appropriate) over 9,000,000 Shares to Dr Kunwar Shailubhai, the Company's Chief Executive Officer and Chief Scientific Officer; (b) options over 400,000 Shares to Tiziano Lazzaretti, the Company's Chief Financial Officer; and (c) options over a further 327,000 Shares to other staff members, all at an exercise price of 35p per share and all conditional on the surrender of all existing share options held by those individuals. The resolutions also included the grant by the Company of options over 3,809,403 Shares to Gabriele Cerrone, the Company's Executive Chairman under the Company's long-term incentive plan at an exercise price of 35p per share and conditional on the surrender of all existing share options held by Mr Cerrone.		The Company entered into an "At the Market" or "ATM" Sales Agreement with Think Equity (a division of Fordham Financial Management, Inc.) to raise up to US$20m from the sale of ADSs (each representing 5 new ordinary shares).
Conversion price, description				The Company issued 6,118,797 new Ordinary Shares of 3 pence each in paid in respect of (i) the conversion of £1,595,322 in face value of its outstanding convertible notes at a conversion price of 42 pence per share (including accrued interest of 16 per cent.); and (ii) the exercise of 1,712,672 warrants at a price of 35 pence per share, yielding £599,435.20 in cash proceeds for the Company and retiring £1,595,322 of indebtedness.
Exercise shares	1,234,399	264,286
Sales Agreement [Member]
Post Balance Sheet Events – Post 31 December 2018 (Textual)
Ordinnary shares					1,743,445
Gross proceeds					$ 1,985,004
Sales amount					$ 348,689
ADSs [Member]
Post Balance Sheet Events – Post 31 December 2018 (Textual)
Issuance of shares						3,333,333
Ordinnary shares						16,666,665
Public per share price						$ 3
Gross proceeds						$ 10,000,000
Ordinary shares, description						Each ADS offered represents five (5) Ordinary Shares (reduced from 10 ordinary shares in a stock split that took place in October 2019. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 499,999 ADSs on the same terms and conditions (the “Option”). All ADSs sold in the Offering were offered by the Company. The number of Ordinary Shares represented by ADSs comprised in the Offering (including by way of the exercise of the Option) were within existing shareholder authorities.
Euro [Member]
Post Balance Sheet Events – Post 31 December 2018 (Textual)
Nominal value						$ 0.03
GBP [Member]
Post Balance Sheet Events – Post 31 December 2018 (Textual)
Cash proceeds	$ 578,700	$ 132,143

Financial Commitments (Details)

Financial Commitments (Details)	12 Months Ended
	Dec. 31, 2019
Financial Commitments (Textual)
Financial commitments, description	The Executive Chairman is also eligible to receive two realisation bonuses as follows: (c) in the event that, either: (i) the Group raises, in one or a series of transactions, new equity capital in excess of £20,000,000 (after expenses); or (ii) there is a sale, in one or a series of transactions, of all or substantially all of the assets (calculated on the basis of book values) of the Group Companies (or a licence of the same on an exclusive or non-exclusive basis), where the Enterprise Value equals or exceeds £150,000,000; or (iii) there is a change of control where the Enterprise Value equals or exceeds £150,000,000, in which case the Realisation Bonus will be the amount equal to the Enterprise Value multiplied by two and a half (2.5) per cent; (d) In addition to the payment of the Realisation Bonus outlined above, in the event that, during this Agreement, either: (i) there is a sale, in one or a series of transactions, of all or substantially all of the assets ( calculated on the basis of book values) of the Group ( or a licence of the same on an exclusive or non-exclusive basis ), where • the Enterprise Value equals or exceeds £300;000,000; or (ii) there is either a change of control where the Enterprise Value equals or exceeds £300,000,000, the Chairman will be entitled to receive an additional Realisation Bonus in the amount equal to the Enterprise Value multiplied by three and a half (3.5) per cent.